Cat. No.: HY-50896

Erlotinib

(Synonyms: CP-358774; NSC 718781; OSI-774)

138 Cited Publications

Customer Review

Based on 138 publication(s) in Google Scholar

Erlotinib (CP-358774) is a selective, orally active EGFR tyrosine kinase inhibitor. Erlotinib also acts as a substrate and inhibitor of OATP2B1, with an IC₅₀ of approximately 0.079 μM for inhibiting OATP2B1-mediated uptake of estrone 3-sulfate. Erlotinib blocks EGFR phosphorylation, downstream signal transduction, as well as the growth and proliferation of cancer cells. Erlotinib inhibits MMP-10-mediated renal injury, fibrotic lesions, the ERK1/2, GSK-3β and β-catenin signaling pathways, fibronectin, α-SMA, collagen deposition, and renal injury markers. Erlotinib is metabolized via CYP3A to produce the active metabolite OSI-420. Erlotinib can be used in research related to non-small cell lung cancer, gastric cancer, papillary renal cell carcinoma, pancreatic cancer, renal fibrosis, and other conditions.

For research use only. We do not sell to patients.

Purity: 99.96%
CAS No.: 183321-74-6
Formula: C₂₂H₂₃N₃O₄
Molecular Weight:393.44

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Erlotinib Chemical Structure

CAS No.: 183321-74-6

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Antibody-Drug Conjugates

One-stop solution for XDC (ADC/PDC/RDC/ApDC/FDC/ISAC/VDC/SMDC)

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- Parmacokinetics
- In Vivo
Chemical Information
Publications (138)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target^[2]^[4]^[5]

EGFR

OATP2B1

β-catenin

ERK1

ERK2

GSK-3β

All EGFR Isoforms :

All ERK Isoforms :

All GSK-3 Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
16HBE14o-	CC₅₀	1.32 μM Compound: Erlotinib	Cytotoxicity against human 16HBE14o- cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human 16HBE14o- cells assessed as inhibition of cell growth by MTT assay	[PMID: 36509365]
A-375	IC₅₀	5.12 μM Compound: 1	Antiproliferative activity against human A375 cells after 48 hrs by propidium iodide fluorescence assay Antiproliferative activity against human A375 cells after 48 hrs by propidium iodide fluorescence assay	[PMID: 30744932]
A-375	IC₅₀	27.26 μM Compound: Erlotinib	Antiproliferative activity aganist human A375 cells incubated for 72 hrs by MTT assay Antiproliferative activity aganist human A375 cells incubated for 72 hrs by MTT assay	[PMID: 31493743]
A-375	IC₅₀	17.86 μM Compound: Erlotinib	Cytotoxicity against human A-375 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human A-375 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 35685617]
A-375	IC₅₀	25.85 μM Compound: Erlotinib	Antiproliferative activity against human A-375 cells incubated for 24 hrs by MTT assay Antiproliferative activity against human A-375 cells incubated for 24 hrs by MTT assay	[PMID: 36513215]
A-431	IC₅₀	0.608 μg/mL Compound: 2 (Tarceva)	Inhibition of A431 cell proliferation Inhibition of A431 cell proliferation	[PMID: 12270171]
A-431	GI₅₀	0.47 μM Compound: Tarceva	Growth inhibition of human A431 cells overexpressing EGFR after 72 hrs by MTT assay Growth inhibition of human A431 cells overexpressing EGFR after 72 hrs by MTT assay	[PMID: 17983745]
A-431	IC₅₀	96 nM Compound: 2	Cytotoxicity against human A431 cells after 72 hrs by SRB assay Cytotoxicity against human A431 cells after 72 hrs by SRB assay	[PMID: 19888761]
A-431	GI₅₀	0.915 μM Compound: Tar	Growth inhibition of human A431 cells after 72 hrs by MTT assay Growth inhibition of human A431 cells after 72 hrs by MTT assay	[PMID: 19969465]
A-431	IC₅₀	34 nM Compound: Erlotinib	Inhibition of EGFR intracellular phosphorylation in human A431 cells by ELISA Inhibition of EGFR intracellular phosphorylation in human A431 cells by ELISA	[PMID: 20346655]
A-431	IC₅₀	>10000 nM Compound: Erlotinib	Inhibition of IGF1R intracellular phosphorylation in human A431 cells by ELISA Inhibition of IGF1R intracellular phosphorylation in human A431 cells by ELISA	[PMID: 20346655]
A-431	IC₅₀	1.2 μM Compound: 1	Inhibition of EGFR phosphorylation in human A431 cells after 10 mins by FLISA Inhibition of EGFR phosphorylation in human A431 cells after 10 mins by FLISA	[PMID: 20403700]
A-431	IC₅₀	1.2 μM Compound: Erlotinib	Inhibition of EGFR expressed in human A431 cells Inhibition of EGFR expressed in human A431 cells	[PMID: 20558072]
A-431	IC₅₀	124.7 μM Compound: Erlotinib	Inhibition of VEGFR2 expressed in human A431 cells Inhibition of VEGFR2 expressed in human A431 cells	[PMID: 20558072]
A-431	IC₅₀	83.1 μM Compound: Erlotinib	Inhibition of PDGFRbeta expressed in human A431 cells Inhibition of PDGFRbeta expressed in human A431 cells	[PMID: 20558072]
A-431	IC₅₀	1.9 μM Compound: Chemical Probe: Erlotinib	Antiproliferative activity against human A-431 cells assessed as reduction in cell proliferation measured after 72 hrs by celltiter-glo assay Antiproliferative activity against human A-431 cells assessed as reduction in cell proliferation measured after 72 hrs by celltiter-glo assay	[PMID: 20571069]
A-431	IC₅₀	1.2 μM Compound: 1	Inhibition of EGFR tyrosine kinase activity in EGF-stimulated human A431 cells after 60 mins by ELISA Inhibition of EGFR tyrosine kinase activity in EGF-stimulated human A431 cells after 60 mins by ELISA	[PMID: 22204741]
A-431	IC₅₀	55 nM Compound: Erlotinib	Cytotoxicity against human A431 cells over expressing EGFR after 48 hrs by MTT assay Cytotoxicity against human A431 cells over expressing EGFR after 48 hrs by MTT assay	[PMID: 22414612]
A-431	IC₅₀	1.2 μM Compound: Erlotinib	Inhibition of EGFR in human A431 cells pretreated for 60 mins measured after 1 hr by ELISA Inhibition of EGFR in human A431 cells pretreated for 60 mins measured after 1 hr by ELISA	[PMID: 22739090]
A-431	IC₅₀	1.87 μg/mL Compound: Erlotinib	Antiproliferative activity against human A431 cells after 24 to 48 hrs by WST1 assay Antiproliferative activity against human A431 cells after 24 to 48 hrs by WST1 assay	[PMID: 22901387]
A-431	IC₅₀	1.2 μM Compound: 2	Inhibition of EGF-induced EGFR phosphorylation in human A431 cells overexpressing EGFR pretreated for 60 mins prior to EGF addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis Inhibition of EGF-induced EGFR phosphorylation in human A431 cells overexpressing EGFR pretreated for 60 mins prior to EGF addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis	[PMID: 23375090]
A-431	IC₅₀	1.2 μM Compound: Erlotinib	Inhibition of EGFR in human A431 cells assessed as inhibition of EGF-induced tyrosine phosphorylation incubated for 60 mins prior to EGF-activation measured 10 mins by ELISA Inhibition of EGFR in human A431 cells assessed as inhibition of EGF-induced tyrosine phosphorylation incubated for 60 mins prior to EGF-activation measured 10 mins by ELISA	[PMID: 23434139]
A-431	IC₅₀	0.409 μM Compound: 2	Antiproliferative activity against human A431 cells after 72 hrs by SRB assay Antiproliferative activity against human A431 cells after 72 hrs by SRB assay	[PMID: 24183742]
A-431	IC₅₀	0.75 μM Compound: Erlotinib, Tarceva	Cytotoxicity against human A431 cells expressing EGFR after 72 hrs by MTT assay Cytotoxicity against human A431 cells expressing EGFR after 72 hrs by MTT assay	[PMID: 24411123]
A-431	IC₅₀	0.56 μM Compound: 2	Antiproliferative activity against human A431 cells assessed as growth inhibition after 72 hrs by SRB assay Antiproliferative activity against human A431 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 24565969]
A-431	IC₅₀	1.2 nM Compound: Erlotinib	Inhibition of EGFR in human A431 cells by phosphotyrosine ELISA assay Inhibition of EGFR in human A431 cells by phosphotyrosine ELISA assay	[PMID: 24890652]
A-431	IC₅₀	1.2 nM Compound: Erlotinib	Inhibition of EGFR in human A431 cells compound pretreated for 60 min before EGF stimulation for 10 mins by phosphotyrosine ELISA cytoblot method Inhibition of EGFR in human A431 cells compound pretreated for 60 min before EGF stimulation for 10 mins by phosphotyrosine ELISA cytoblot method	[PMID: 25882519]
A-431	IC₅₀	0.844 μM Compound: Erlotinib	Antiproliferative activity against human A431 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human A431 cells after 72 hrs by CCK-8 assay	[PMID: 26487917]
A-431	IC₅₀	0.75 μM Compound: Tarceva	Cytotoxicity against human A431 cells overexpressing EGFR assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A431 cells overexpressing EGFR assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 27524310]
A-431	IC₅₀	0.4 μM Compound: Erlotinib	Antiproliferative activity against human A431 cells Antiproliferative activity against human A431 cells	[PMID: 27614407]
A-431	IC₅₀	5.14 μM Compound: Erlotinib	Antiproliferative activity against human A431 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human A431 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31078412]
A-431	IC₅₀	2.2 μM Compound: 2	Antiproliferative activity against human A-431 cells harboring wild type EGFR assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human A-431 cells harboring wild type EGFR assessed as inhibition of cell growth by MTT assay	[PMID: 31869655]
A-431	IC₅₀	0.75 μM Compound: Erlotinib	Antiproliferative activity against human A431 cells overexpressing EGFR assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human A431 cells overexpressing EGFR assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 32139324]
A-431	IC₅₀	1.41 μM Compound: Erlotinib	Cytotoxicity against human A-431 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human A-431 cells assessed as reduction in cell viability by MTT assay	[PMID: 32320239]
A-431	IC₅₀	11.85 μM Compound: Erlotinib	Antiproliferative activity against human A-431 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human A-431 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33640672]
A-431	IC₅₀	28.7 μM Compound: Erlotinib	Cytotoxicity against human A-431 cells expressing EGFR assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human A-431 cells expressing EGFR assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34046625]
A-431	IC₅₀	31.94 μM Compound: Erlotinib	Antiproliferative activity against human A-431 cells overexpressing EGFR assessed as cell growth inhibition by MTT assay Antiproliferative activity against human A-431 cells overexpressing EGFR assessed as cell growth inhibition by MTT assay	[PMID: 34995690]
A-431	EC₅₀	2805 nM Compound: 16	Cytotoxicity against human A-431 cells expressing wild type EGFR assessed as reduction in cell viability incubated for 96 hrs by CellTiter-Glo assay Cytotoxicity against human A-431 cells expressing wild type EGFR assessed as reduction in cell viability incubated for 96 hrs by CellTiter-Glo assay	[PMID: 37197473]
A-431	GI₅₀	222 nM Compound: 1	Antiproliferative activity against human A-431 cells harboring EGFR assessed as cell growth inhibition incubated for 72 hrs by Celltiter Glo assay Antiproliferative activity against human A-431 cells harboring EGFR assessed as cell growth inhibition incubated for 72 hrs by Celltiter Glo assay	[PMID: 37499291]
A-431	IC₅₀	2.5 μM Compound: 6	Cytotoxicity against human A431 cells by Alamar Blue assay Cytotoxicity against human A431 cells by Alamar Blue assay	10.1039/C2MD00317A
A498	IC₅₀	25.6 μM Compound: 2	Antiproliferative activity against human A498 cells expressing EGFR and Src after 48 hrs by SRB assay Antiproliferative activity against human A498 cells expressing EGFR and Src after 48 hrs by SRB assay	[PMID: 26188620]
A498	IC₅₀	12500 nM Compound: Erlotinib	Antiproliferative activity against human A498 cells after 48 hrs by MTT assay Antiproliferative activity against human A498 cells after 48 hrs by MTT assay	[PMID: 29057042]
A549	IC₅₀	33.03 μM Compound: Erlotinib	Cytotoxicity against human A549 cells after 4 to 5 days by MTT assay Cytotoxicity against human A549 cells after 4 to 5 days by MTT assay	[PMID: 20466555]
A549	IC₅₀	0.13 μg/mL Compound: Erlotinib, ZD-1839	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 21763148]
A549	IC₅₀	0.27 μM Compound: Erlotinib, ZD-1839	Antiproliferative activity against human A549 cells expressing EGFR assessed as inhibition of basal cell growth after 48 hrs by MTT assay Antiproliferative activity against human A549 cells expressing EGFR assessed as inhibition of basal cell growth after 48 hrs by MTT assay	[PMID: 21763148]
A549	IC₅₀	0.13 μg/mL Compound: Erlotinib	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 21920766]
A549	IC₅₀	9.48 μg/mL Compound: Erlotinib	Antiproliferative activity against human A549 cells after 24 to 48 hrs by WST1 assay Antiproliferative activity against human A549 cells after 24 to 48 hrs by WST1 assay	[PMID: 22901387]
A549	GI₅₀	0.03 μM Compound: Erlotinib	Antiproliferative activity against human A549 cells after 24 hrs by MTT assay Antiproliferative activity against human A549 cells after 24 hrs by MTT assay	[PMID: 23391364]
A549	IC₅₀	0.13 μM Compound: Erlotinib	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 23962660]
A549	IC₅₀	0.13 μM Compound: Erlotinib	Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 24144854]
A549	IC₅₀	0.13 μM Compound: Erlotinib	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 24607998]
A549	IC₅₀	0.13 μM Compound: Erlotinib	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 24630412]
A549	IC₅₀	7.099 μM Compound: Erlotinib	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 24900830]
A549	IC₅₀	0.1 μM Compound: Erlotinib	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 25172421]
A549	IC₅₀	7.59 μM Compound: 4	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation under normoxia conditions after 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation under normoxia conditions after 72 hrs by SRB assay	[PMID: 25468044]
A549	IC₅₀	9.1 μM Compound: 4	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation under hypoxia conditions after 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation under hypoxia conditions after 72 hrs by SRB assay	[PMID: 25468044]
A549	IC₅₀	11 nM Compound: 3	Inhibition of EGF-stimulated wild type EGFR autophosphorylation expressed in human A549 cells by sandwich ELISA Inhibition of EGF-stimulated wild type EGFR autophosphorylation expressed in human A549 cells by sandwich ELISA	[PMID: 26756222]
A549	IC₅₀	6.26 μM Compound: Erlotinib	Antiproliferative activity against human A549 cells assessed as viable cells after 48 hrs by CCK8 assay Antiproliferative activity against human A549 cells assessed as viable cells after 48 hrs by CCK8 assay	[PMID: 26879314]
A549	IC₅₀	0.02 μM Compound: Erlotinib	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by propidium iodide staining based fluorometer assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by propidium iodide staining based fluorometer assay	[PMID: 27010345]
A549	EC₅₀	>1000 nM Compound: Erlotinib	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 27010810]
A549	IC₅₀	7.35 μM Compound: Erlotinib	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by cck8 assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by cck8 assay	[PMID: 27234887]
A549	IC₅₀	>100 μM Compound: Erlotinib	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by Cell Titer Glo luminescent cell viability assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by Cell Titer Glo luminescent cell viability assay	[PMID: 27614407]
A549	IC₅₀	21.3 μM Compound: Erlotinib	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 28886509]
A549	IC₅₀	0.73 μM Compound: Erlotinib	Cytotoxicity against human A549 cells after 24 hrs by MTT assay Cytotoxicity against human A549 cells after 24 hrs by MTT assay	[PMID: 29028534]
A549	IC₅₀	0.04 μM Compound: Erlotinib	Antiproliferative activity human A549 cells after 48 hrs by propidium iodide staining-based fluorescence assay Antiproliferative activity human A549 cells after 48 hrs by propidium iodide staining-based fluorescence assay	[PMID: 29407956]
A549	IC₅₀	17.32 μM Compound: Erlotinib	Anticancer activity against human A549 cells assessed as reduction in cell viability after 96 hrs by MTT assay Anticancer activity against human A549 cells assessed as reduction in cell viability after 96 hrs by MTT assay	[PMID: 29549841]
A549	IC₅₀	10.39 μM Compound: 1; Erlo	Antiproliferative activity against human A549 cells after 24 hrs by MTT assay Antiproliferative activity against human A549 cells after 24 hrs by MTT assay	[PMID: 30108891]
A549	IC₅₀	4.28 μM Compound: Erlotinib	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 30503938]
A549	IC₅₀	10.26 μM Compound: Erlotinib	Cytotoxicity against human A549 cells after 24 hrs by MTT assay Cytotoxicity against human A549 cells after 24 hrs by MTT assay	[PMID: 30562699]
A549	IC₅₀	0.064 μM Compound: Erlotinib	Inhibition of human HER2 in human A549 cells by ELISA method Inhibition of human HER2 in human A549 cells by ELISA method	[PMID: 30826508]
A549	IC₅₀	27.55 μM Compound: Erlotinib	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31078412]
A549	IC₅₀	0.03 μM Compound: ERL	Cytotoxicity against human A549 Cells by MTT assay Cytotoxicity against human A549 Cells by MTT assay	[PMID: 31129455]
A549	IC₅₀	20 μM Compound: Erlotinib	Antiproliferative activity against wild type human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against wild type human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31446247]
A549	IC₅₀	22.35 μM Compound: Erlotinib	Antiproliferative activity aganist human A549 cells incubated for 72 hrs by MTT assay Antiproliferative activity aganist human A549 cells incubated for 72 hrs by MTT assay	[PMID: 31493743]
A549	IC₅₀	3.8 μM Compound: Erlotinib	Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay	[PMID: 31671308]
A549	IC₅₀	11.8 μM Compound: Erlotinib	Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay	[PMID: 32320239]
A549	IC₅₀	0.008 μM Compound: Erlotinib	Antiproliferative activity against human A549 cells harboring wild type EGFR assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human A549 cells harboring wild type EGFR assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32402937]
A549	IC₅₀	>50 μM Compound: Erlotinib	Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	[PMID: 32739648]
A549	IC₅₀	0.22 μM Compound: Erlotinib	Anticancer activity against human A549 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay Anticancer activity against human A549 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	[PMID: 32739648]
A549	IC₅₀	2.98 μM Compound: Erlotinib	Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 32739648]
A549	IC₅₀	2.63 μM Compound: Erlotinib	Antiproliferative activity against human A549 cells assessed as reduction in cell growth by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell growth by MTT assay	[PMID: 32949719]
A549	IC₅₀	16.83 μM Compound: Erlotinib	Antiproliferative activity against human A549 cells Antiproliferative activity against human A549 cells	[PMID: 32961382]
A549	IC₅₀	20.86 μM Compound: Erlotinib	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 33423463]
A549	IC₅₀	1.04 μM Compound: Erlotinib	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 33479688]
A549	IC₅₀	16.43 μM Compound: Erlotinib	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33640672]
A549	IC₅₀	10 μM Compound: Erlotinib	Cytotoxicity against human A549 cells incubated for 2 to 4 hrs by MTT assay Cytotoxicity against human A549 cells incubated for 2 to 4 hrs by MTT assay	[PMID: 33771586]
A549	IC₅₀	47.74 μM Compound: Erlotinib	Cytotoxicity against human A549 cells expressing EGFR assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human A549 cells expressing EGFR assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34046625]
A549	IC₅₀	11.68 μM Compound: Erlotinib	Anticancer activity against human A549 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay based microtiter plate analysis Anticancer activity against human A549 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay based microtiter plate analysis	[PMID: 34438126]
A549	EC₅₀	0.29 μM Compound: Erlotinib	Cytotoxicity against human A549 cells measured after 48 hrs by MTT assay Cytotoxicity against human A549 cells measured after 48 hrs by MTT assay	[PMID: 35569690]
A549	IC₅₀	17.86 μM Compound: Erlotinib	Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 35685617]
A549	IC₅₀	34.16 μM Compound: Erlotinib	Antiproliferative activity against human A549 cells incubated for 24 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 24 hrs by MTT assay	[PMID: 36513215]
A549	IC₅₀	10.2 μM Compound: Erlotinib	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth by MTT assay	[PMID: 36893627]
A549	IC₅₀	1.23 μM Compound: Erlotinib	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37122544]
A549	IC₅₀	30 nM Compound: Erlotinib	Antiproliferative activity against human A549 cells by MTT assay Antiproliferative activity against human A549 cells by MTT assay	[PMID: 37122549]
A549	IC₅₀	19.75 μM Compound: Erlotinib	Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 38107169]
A549	IC₅₀	23.53 μM Compound: Erlotinib	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38244939]
A549	IC₅₀	7.74 μM Compound: Erlotinib	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs in presence of 10-hydroxyl-evodiamine by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs in presence of 10-hydroxyl-evodiamine by MTT assay	[PMID: 38244939]
A549	IC₅₀	9.19 μM Compound: Erlotinib	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs in presence of evodiamine by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs in presence of evodiamine by MTT assay	[PMID: 38244939]
A549	IC₅₀	30 nM Compound: Erlotinib	Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay	[PMID: 39026636]
A549	IC₅₀	4.68 μM Compound: Erlotinib	Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay	[PMID: 39026650]
A549	IC₅₀	52.17 μM Compound: Erlotinib	Cytotoxicity against human A549 cells incubated for 24 hrs by MTT assay Cytotoxicity against human A549 cells incubated for 24 hrs by MTT assay	[PMID: 39047611]
A549	IC₅₀	>50 μM Compound: 6	Cytotoxicity against human A549 cells by Alamar Blue assay Cytotoxicity against human A549 cells by Alamar Blue assay	10.1039/C2MD00317A
AU565	IC₅₀	3.3 μM Compound: Erlotinib	Antiproliferative activity against human AU565 cells incubated for 72 hrs by ATPlite luminescence assay Antiproliferative activity against human AU565 cells incubated for 72 hrs by ATPlite luminescence assay	[PMID: 27614407]
B16-F10	IC₅₀	0.02 μg/mL Compound: Erlotinib, ZD-1839	Antiproliferative activity against mouse B16F10 cells assessed as inhibition of serum-stimulated cell growth after 48 hrs by MTT assay Antiproliferative activity against mouse B16F10 cells assessed as inhibition of serum-stimulated cell growth after 48 hrs by MTT assay	[PMID: 21763148]
B16-F10	IC₅₀	0.022 μg/mL Compound: Erlotinib	Antiproliferative activity against mouse B16-F10 cells after 48 hrs by MTT assay Antiproliferative activity against mouse B16-F10 cells after 48 hrs by MTT assay	[PMID: 21920766]
B16-F10	IC₅₀	0.1 μM Compound: Tarceva	Antiproliferative activity against mouse B16F10 cells after 48 hrs by MTT assay Antiproliferative activity against mouse B16F10 cells after 48 hrs by MTT assay	[PMID: 22361272]
B16-F10	IC₅₀	0.94 μg/mL Compound: Erlotinib	Antiproliferative activity against mouse B16F10 cells after 24 to 48 hrs by WST1 assay Antiproliferative activity against mouse B16F10 cells after 24 to 48 hrs by WST1 assay	[PMID: 22901387]
B16-F10	IC₅₀	0.05 μM Compound: Erlotinib	Antiproliferative activity against mouse B16/F10 cells after 48 hrs by MTT assay Antiproliferative activity against mouse B16/F10 cells after 48 hrs by MTT assay	[PMID: 23245802]
B16-F10	IC₅₀	0.17 μM Compound: Erlotinib	Antiproliferative activity against mouse B16F10 cells after 12 hrs by MTT assay Antiproliferative activity against mouse B16F10 cells after 12 hrs by MTT assay	[PMID: 26652482]
B16-F10	IC₅₀	0.12 μM Compound: Erlotinib	Antiproliferative activity against mouse B16F10 cells after 48 hrs by MTT assay Antiproliferative activity against mouse B16F10 cells after 48 hrs by MTT assay	[PMID: 28988624]
BaF3	IC₅₀	12.5 nM Compound: erlotinib	Cytotoxicity against mouse BA/F3 cells expressing EGFR L858R mutant Cytotoxicity against mouse BA/F3 cells expressing EGFR L858R mutant	[PMID: 19239229]
BaF3	GI₅₀	<0.5 μM Compound: Erlotinib	Growth inhibition of mouse BA/F3 cells expressing EGFR Del1 mutant after 96 hrs by cell titer-glo assay Growth inhibition of mouse BA/F3 cells expressing EGFR Del1 mutant after 96 hrs by cell titer-glo assay	[PMID: 20222733]
BaF3	GI₅₀	<0.5 μM Compound: Erlotinib	Growth inhibition of mouse BA/F3 cells expressing EGFR Del3 mutant after 96 hrs by cell titer-glo assay Growth inhibition of mouse BA/F3 cells expressing EGFR Del3 mutant after 96 hrs by cell titer-glo assay	[PMID: 20222733]
BaF3	GI₅₀	<0.5 μM Compound: Erlotinib	Growth inhibition of mouse BA/F3 cells expressing EGFR Del5 mutant after 96 hrs by cell titer-glo assay Growth inhibition of mouse BA/F3 cells expressing EGFR Del5 mutant after 96 hrs by cell titer-glo assay	[PMID: 20222733]
BaF3	GI₅₀	<0.5 μM Compound: Erlotinib	Growth inhibition of mouse BA/F3 cells expressing EGFR L858R mutant after 96 hrs by cell titer-glo assay Growth inhibition of mouse BA/F3 cells expressing EGFR L858R mutant after 96 hrs by cell titer-glo assay	[PMID: 20222733]
BaF3	GI₅₀	>5 μM Compound: Erlotinib	Growth inhibition of mouse BA/F3 cells expressing EGFR Del1 and Thr790Met mutant after 96 hrs by cell titer-glo assay Growth inhibition of mouse BA/F3 cells expressing EGFR Del1 and Thr790Met mutant after 96 hrs by cell titer-glo assay	[PMID: 20222733]
BaF3	GI₅₀	>5 μM Compound: Erlotinib	Growth inhibition of mouse BA/F3 cells expressing EGFR Del3 and Thr790Met mutant after 96 hrs by cell titer-glo assay Growth inhibition of mouse BA/F3 cells expressing EGFR Del3 and Thr790Met mutant after 96 hrs by cell titer-glo assay	[PMID: 20222733]
BaF3	GI₅₀	>5 μM Compound: Erlotinib	Growth inhibition of mouse BA/F3 cells expressing EGFR Del5 and Thr790Met mutant after 96 hrs by cell titer-glo assay Growth inhibition of mouse BA/F3 cells expressing EGFR Del5 and Thr790Met mutant after 96 hrs by cell titer-glo assay	[PMID: 20222733]
BaF3	GI₅₀	>5 μM Compound: Erlotinib	Growth inhibition of mouse BA/F3 cells expressing EGFR L858R and Thr790Met mutant after 96 hrs by cell titer-glo assay Growth inhibition of mouse BA/F3 cells expressing EGFR L858R and Thr790Met mutant after 96 hrs by cell titer-glo assay	[PMID: 20222733]
BaF3	IC₅₀	87 nM Compound: Erlotinib	Inhibition of EGFR L858R mutant (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by XTT assay Inhibition of EGFR L858R mutant (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by XTT assay	[PMID: 27235841]
BaF3	IC₅₀	87 nM Compound: Erlotinib	Antiproliferative activity against mouse Ba/F3 cells expressing EGFR-L858R mutant assessed as inhibition of cell growth incubated for 48 hrs by XTT assay Antiproliferative activity against mouse Ba/F3 cells expressing EGFR-L858R mutant assessed as inhibition of cell growth incubated for 48 hrs by XTT assay	[PMID: 27614407]
BaF3	EC₅₀	16 nM Compound: 16	Cytotoxicity against mouse BaF3 cells expressing EGFR L858R/C797S mutant assessed as reduction in cell viability incubated for 96 hrs by CellTiter-Glo assay Cytotoxicity against mouse BaF3 cells expressing EGFR L858R/C797S mutant assessed as reduction in cell viability incubated for 96 hrs by CellTiter-Glo assay	[PMID: 37197473]
BaF3	GI₅₀	112.7 nM Compound: 1	Antiproliferative activity against mouse BaF3 cells harboring TEL-EGFR-C797S mutant assessed as cell growth inhibition incubated for 72 hrs by Celltiter Glo assay Antiproliferative activity against mouse BaF3 cells harboring TEL-EGFR-C797S mutant assessed as cell growth inhibition incubated for 72 hrs by Celltiter Glo assay	[PMID: 37499291]
BaF3	IC₅₀	2320 nM Compound: Erlotinib	Antiproliferative activity against mouse BaF3 cells harboring EGFR-D770-N771insNPG mutant incubated for 3 days by Cell Titer-Glo assay Antiproliferative activity against mouse BaF3 cells harboring EGFR-D770-N771insNPG mutant incubated for 3 days by Cell Titer-Glo assay	[PMID: 37669428]
BaF3	IC₅₀	71 nM Compound: Erlotinib	Antiproliferative activity against mouse BaF3 cells harboring wild type EGFR incubated for 3 days by Cell Titer-Glo assay Antiproliferative activity against mouse BaF3 cells harboring wild type EGFR incubated for 3 days by Cell Titer-Glo assay	[PMID: 37669428]
BGC-823	IC₅₀	11.79 μM Compound: 3a; Erlotinib	Antiproliferative activity against human BGC-823 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human BGC-823 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34416665]
BT-474	IC₅₀	6730 nM Compound: Erlotinib	Inhibition of ERBb2 phosphorylation in human BT474 cells by ELISA Inhibition of ERBb2 phosphorylation in human BT474 cells by ELISA	[PMID: 20817523]
BT-474	IC₅₀	>10 μM Compound: Erlotinib, Tarceva	Cytotoxicity against human BT474 cells expressing HER2 after 72 hrs by MTT assay Cytotoxicity against human BT474 cells expressing HER2 after 72 hrs by MTT assay	[PMID: 24411123]
BT-474	IC₅₀	13 μM Compound: Erlotinib	Antiproliferative activity against human BT474 cells after 72 hrs by CellTiter blue assay Antiproliferative activity against human BT474 cells after 72 hrs by CellTiter blue assay	[PMID: 26599532]
BT-474	IC₅₀	>10 μM Compound: Tarceva	Cytotoxicity against human BT474 cells overexpressing HER2 assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human BT474 cells overexpressing HER2 assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 27524310]
BT-474	IC₅₀	>10 μM Compound: Erlotinib	Antiproliferative activity against human BT474 cells overexpressing HER2 assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human BT474 cells overexpressing HER2 assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 32139324]
BXPC-3	IC₅₀	7.6 μM Compound: erlotinib	Antiproliferative activity against human BxPC3 cells after hrs by ATP content assay Antiproliferative activity against human BxPC3 cells after hrs by ATP content assay	[PMID: 20143778]
BXPC-3	EC₅₀	>1000 nM Compound: Erlotinib	Antiproliferative activity against human BxPC3 cells after 72 hrs by MTT assay Antiproliferative activity against human BxPC3 cells after 72 hrs by MTT assay	[PMID: 27010810]
BXPC-3	IC₅₀	1.9 μM Compound: Erlotinib	Antiproliferative activity against human BXPC-3 cells measured for 96 hrs by sytox green dye staining based proliferation assay Antiproliferative activity against human BXPC-3 cells measured for 96 hrs by sytox green dye staining based proliferation assay	[PMID: 27614407]
C-33-A	IC₅₀	0.9 μM Compound: Erlotinib	Antiproliferative activity against human C-33A cells incubated for 72 hrs by ATPlite luminescence assay Antiproliferative activity against human C-33A cells incubated for 72 hrs by ATPlite luminescence assay	[PMID: 27614407]
CAKI-2	EC₅₀	>1000 nM Compound: Erlotinib	Antiproliferative activity against human Caki2 cells after 72 hrs by MTT assay Antiproliferative activity against human Caki2 cells after 72 hrs by MTT assay	[PMID: 27010810]
CAL-27	IC₅₀	10.15 μM Compound: erlotinib	Antiproliferative activity against human CAL27 cells Antiproliferative activity against human CAL27 cells	[PMID: 20143778]
CAL-27	IC₅₀	0.239 μM Compound: 3, Tarceva	Cytotoxicity against human CAL27 cells after 4 days by propidium iodide staining-based fluorometric analysis Cytotoxicity against human CAL27 cells after 4 days by propidium iodide staining-based fluorometric analysis	[PMID: 22169601]
CAL-27	IC₅₀	1.3 μM Compound: Erlotinib	Antiproliferative activity against human CAL27 cells Antiproliferative activity against human CAL27 cells	[PMID: 27614407]
CAL-27	IC₅₀	0.074 μM Compound: 6	Cytotoxicity against human CAL27 cells by Alamar Blue assay Cytotoxicity against human CAL27 cells by Alamar Blue assay	10.1039/C2MD00317A
Calu-3	IC₅₀	0.93 μM Compound: Erlotinib, Tarceva	Cytotoxicity against human Calu3 cells expressing HER2 after 72 hrs by MTT assay Cytotoxicity against human Calu3 cells expressing HER2 after 72 hrs by MTT assay	[PMID: 24411123]
Calu-3	IC₅₀	4.7 μM Compound: Erlotinib	Antiproliferative activity against human Calu3 cells after 72 hrs by CellTiter blue assay Antiproliferative activity against human Calu3 cells after 72 hrs by CellTiter blue assay	[PMID: 26599532]
Calu-3	IC₅₀	0.926 μM Compound: Erlotinib	Antiproliferative activity against human Calu3 cells overexpressing HER2 assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human Calu3 cells overexpressing HER2 assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 32139324]
Calu-6	IC₅₀	35.6 μM Compound: Chemical Probe: Erlotinib	Antiproliferative activity against human Calu-6 cells assessed as reduction in cell proliferation measured after 72 hrs by celltiter-glo assay Antiproliferative activity against human Calu-6 cells assessed as reduction in cell proliferation measured after 72 hrs by celltiter-glo assay	[PMID: 20571069]
CAPAN-1	IC₅₀	>20 μM Compound: erlotinib	Antiproliferative activity against human Capan1 cells after hrs by ATP content assay Antiproliferative activity against human Capan1 cells after hrs by ATP content assay	[PMID: 20143778]
CL97	IC₅₀	>20 μM Compound: Erlotinib	Antiproliferative activity against human CL97 cells harbouring EGFR G719A/T790M mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human CL97 cells harbouring EGFR G719A/T790M mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31446247]
COS-7	IC₅₀	>20 μM Compound: erlotinib	Inhibition of human JAK2 expressed in COS7 cells Inhibition of human JAK2 expressed in COS7 cells	[PMID: 17178722]
COS-7	IC₅₀	4 μM Compound: erlotinib	Inhibition of human JAK2 V617F mutant expressed in COS7 cells Inhibition of human JAK2 V617F mutant expressed in COS7 cells	[PMID: 17178722]
CWR22R	IC₅₀	100 μM Compound: 3, Tarceva	Cytotoxicity against human 22Rv1 cells after 4 days by propidium iodide staining-based fluorometric analysis Cytotoxicity against human 22Rv1 cells after 4 days by propidium iodide staining-based fluorometric analysis	[PMID: 22169601]
DU-145	IC₅₀	19.4 μM Compound: Erlotinib	Cytotoxicity against human DU145 cells after 4 to 5 days by MTT assay Cytotoxicity against human DU145 cells after 4 to 5 days by MTT assay	[PMID: 20466555]
DU-145	IC₅₀	0.966 μM Compound: 3, Tarceva	Cytotoxicity against human DU145 cells after 4 days by propidium iodide staining-based fluorometric analysis Cytotoxicity against human DU145 cells after 4 days by propidium iodide staining-based fluorometric analysis	[PMID: 22169601]
DU-145	IC₅₀	18.4 μM Compound: 1; Erlo	Antiproliferative activity against human DU145 cells after 24 hrs by MTT assay Antiproliferative activity against human DU145 cells after 24 hrs by MTT assay	[PMID: 30108891]
ECa-109 cell line	IC₅₀	19.22 μM Compound: 3a; Erlotinib	Antiproliferative activity against human EC109 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human EC109 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34416665]
Erythrocyte	IC₅₀	16.23 μM Compound: Erlotinib	Cytotoxicity against human RBC cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human RBC cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31546197]
FaDu	IC₅₀	18 μM Compound: Erlotinib	Antiproliferative activity against human FADU cells Antiproliferative activity against human FADU cells	[PMID: 26599532]
FaDu	IC₅₀	>11 μM Compound: Erlotinib	Antiproliferative activity against human FaDU cells assessed as inhibition of cell growth incubated for 72 hrs by Cell Titer Glo luminescent cell viability assay Antiproliferative activity against human FaDU cells assessed as inhibition of cell growth incubated for 72 hrs by Cell Titer Glo luminescent cell viability assay	[PMID: 27614407]
GES1	IC₅₀	17.99 μM Compound: 3a; Erlotinib	Cytotoxicity against human GES1 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human GES1 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34416665]
H9	IC₅₀	1.3 μM Compound: Erlotinib	Antiproliferative activity against human H9 cells after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human H9 cells after 72 hrs by CellTiter-Glo assay	[PMID: 26599532]
HCC827	IC₅₀	7.5 μM Compound: erlotinib	Antiproliferative activity against human HCC827 cells after hrs by ATP content assay Antiproliferative activity against human HCC827 cells after hrs by ATP content assay	[PMID: 20143778]
HCC827	IC₅₀	0.02 μM Compound: Chemical Probe: Erlotinib	Antiproliferative activity against human HCC827 cells assessed as reduction in cell proliferation measured after 72 hrs by celltiter-glo assay Antiproliferative activity against human HCC827 cells assessed as reduction in cell proliferation measured after 72 hrs by celltiter-glo assay	[PMID: 20571069]
HCC827	IC₅₀	0.002 μM Compound: Erlotinib	Cytotoxicity against human HCC827 cells after 48 hrs by MTT assay Cytotoxicity against human HCC827 cells after 48 hrs by MTT assay	[PMID: 24900830]
HCC827	IC₅₀	0.029 μM Compound: Erlotinib	Antiproliferative activity against human HCC827 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human HCC827 cells after 72 hrs by CCK-8 assay	[PMID: 26487917]
HCC827	GI₅₀	10 nM Compound: 1	Antiproliferative activity against human HCC827 cells harboring EGFR del19 mutant assessed as cell growth inhibition incubated for 72 hrs by Celltiter Glo assay Antiproliferative activity against human HCC827 cells harboring EGFR del19 mutant assessed as cell growth inhibition incubated for 72 hrs by Celltiter Glo assay	[PMID: 37499291]
HCT-116	IC₅₀	65.8 μM Compound: 3, Tarceva	Cytotoxicity against human HCT116 cells after 4 days by propidium iodide staining-based fluorometric analysis Cytotoxicity against human HCT116 cells after 4 days by propidium iodide staining-based fluorometric analysis	[PMID: 22169601]
HCT-116	IC₅₀	0.14 μM Compound: Tarceva	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 22361272]
HCT-116	IC₅₀	7.31 μM Compound: Erlotinib	Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay	[PMID: 30562699]
HCT-116	IC₅₀	11.57 μM Compound: Erlotinib	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31546197]
HCT-116	IC₅₀	23.29 μM Compound: Erlotinib	Antiproliferative activity against human HCT116 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells incubated for 48 hrs by MTT assay	[PMID: 31671308]
HCT-116	IC₅₀	13.91 μM Compound: Erlotinib	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability by SRB assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability by SRB assay	[PMID: 32361329]
HCT-116	IC₅₀	11.21 μM Compound: Erlotinib	Antitumor activity against human HCT-116 cells assessed as inhibition of cell viability by MTT assay Antitumor activity against human HCT-116 cells assessed as inhibition of cell viability by MTT assay	[PMID: 33065442]
HCT-116	IC₅₀	20.46 μM Compound: Erlotinib	Anticancer activity against human HCT-116 cells assessed as cell growth inhibition measured by MTT assay Anticancer activity against human HCT-116 cells assessed as cell growth inhibition measured by MTT assay	[PMID: 34015505]
HCT-116	IC₅₀	17.86 μM Compound: Erlotinib	Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 35685617]
HCT-116	IC₅₀	1.11 μM Compound: Erlotinib	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37122544]
HCT-116	IC₅₀	18.73 μM Compound: Erlotinib	Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 38107169]
HEK293	IC₅₀	0.55 μM Compound: Erlotinib	Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake incubated for 5 mins by scintillation counting Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake incubated for 5 mins by scintillation counting	[PMID: 22541068]
HEK293	IC₅₀	21 μM Compound: Erlotinib	Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake by scintillation counting Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake by scintillation counting	[PMID: 22541068]
HEK293	IC₅₀	44 μM Compound: Erlotinib	Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake incubated for 5 mins by scintillation counting Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake incubated for 5 mins by scintillation counting	[PMID: 22541068]
HEK293	IC₅₀	16.2 μM Compound: Erlotinib	Inhibition of human OCT1 expressed in HEK293 cells assessed as decrease in uptake of ASP+ after 2 mins by fluorescence assay Inhibition of human OCT1 expressed in HEK293 cells assessed as decrease in uptake of ASP+ after 2 mins by fluorescence assay	[PMID: 28230985]
HEK293	IC₅₀	30.3 μM Compound: 1; Erlo	Antiproliferative activity against HEK293 cells after 24 hrs by MTT assay Antiproliferative activity against HEK293 cells after 24 hrs by MTT assay	[PMID: 30108891]
HEK293	IC₅₀	910 nM Compound: Erlotinib	Inhibition of tracer 5 binding to human N-terminal nano luciferase-fused GAK expressed in HEK293 cells measured after 2 hrs by nanoBRET assay Inhibition of tracer 5 binding to human N-terminal nano luciferase-fused GAK expressed in HEK293 cells measured after 2 hrs by nanoBRET assay	[PMID: 30973735]
HEK293	IC₅₀	>32 μM Compound: 6	Inhibition of human recombinant HDAC1 expressed in human HEK293 cells using Ac-NH-GGK(Ac)-AMC as substrate after 180 mins by fluorescence assay Inhibition of human recombinant HDAC1 expressed in human HEK293 cells using Ac-NH-GGK(Ac)-AMC as substrate after 180 mins by fluorescence assay	10.1039/C2MD00317A
HEK293	IC₅₀	>32 μM Compound: 6	Inhibition of human recombinant HDAC6 expressed in human HEK293 cells using Ac-NH-GGK(Ac)-AMC as substrate after 180 mins by fluorescence assay Inhibition of human recombinant HDAC6 expressed in human HEK293 cells using Ac-NH-GGK(Ac)-AMC as substrate after 180 mins by fluorescence assay	10.1039/C2MD00317A
HEK-293T	CC₅₀	104.76 μM Compound: Erlotinib	Cytotoxicity against human HEK293T cells for 24 hrs by MTT assay Cytotoxicity against human HEK293T cells for 24 hrs by MTT assay	[PMID: 26652482]
HEK-293T	CC₅₀	28.22 μM Compound: Erlotinib	Cytotoxicity against HEK293T assessed as reduction in cell viability by MTT assay Cytotoxicity against HEK293T assessed as reduction in cell viability by MTT assay	[PMID: 27234887]
HEK-293T	IC₅₀	73 μM Compound: Erlotinib	Cytotoxicity against human HEK293T cells after 24 hrs by MTT assay Cytotoxicity against human HEK293T cells after 24 hrs by MTT assay	[PMID: 30562699]
HeLa	IC₅₀	0.2 μM Compound: Erlotinib	Antiproliferative activity against human HeLa cells after 12 hrs by MTT assay Antiproliferative activity against human HeLa cells after 12 hrs by MTT assay	[PMID: 26652482]
HeLa	IC₅₀	2.72 μM Compound: Erlotinib	Inhibition of EGFR-TK in human HeLa cells overexpressing EGFR incubated for 18 to 24 hrs by kinase assay Inhibition of EGFR-TK in human HeLa cells overexpressing EGFR incubated for 18 to 24 hrs by kinase assay	[PMID: 31416740]
HeLa	IC₅₀	7.48 μM Compound: Erlotinib	Antiproliferative activity against human HeLa cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HeLa cells incubated for 48 hrs by MTT assay	[PMID: 31671308]
HeLa	IC₅₀	14.93 μM Compound: Erlotinib	Antiproliferative activity against human HeLa cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human HeLa cells assessed as cell growth inhibition by MTT assay	[PMID: 34995690]
HeLa	IC₅₀	>15.8 μM Compound: 6	Inhibition of HDAC in human HeLa cells using Boc-K(Ac)-AMC as substrate preincubated for 4 hrs before substrate addition measured after 3 hrs by fluorescence assay Inhibition of HDAC in human HeLa cells using Boc-K(Ac)-AMC as substrate preincubated for 4 hrs before substrate addition measured after 3 hrs by fluorescence assay	10.1039/C2MD00317A
HeLa	IC₅₀	>32 μM Compound: 6	Inhibition of HDAC in human HeLa cell nuclear extracts using Ac-NH-GGK(Ac)-AMC as substrate after 180 mins by fluorescence assay Inhibition of HDAC in human HeLa cell nuclear extracts using Ac-NH-GGK(Ac)-AMC as substrate after 180 mins by fluorescence assay	10.1039/C2MD00317A
HeLa	IC₅₀	8.3 μM Compound: 6	Cytotoxicity against human HeLa cells by Alamar Blue assay Cytotoxicity against human HeLa cells by Alamar Blue assay	10.1039/C2MD00317A
Hep 3B2	IC₅₀	>20 μM Compound: erlotinib	Antiproliferative activity against human Hep3B2 cells after hrs by ATP content assay Antiproliferative activity against human Hep3B2 cells after hrs by ATP content assay	[PMID: 20143778]
HepG2	IC₅₀	>20 μM Compound: erlotinib	Antiproliferative activity against human HepG2 cells after hrs by ATP content assay Antiproliferative activity against human HepG2 cells after hrs by ATP content assay	[PMID: 20143778]
HepG2	IC₅₀	0.08 μM Compound: Erlotinib	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 21816517]
HepG2	IC₅₀	0.12 μM Compound: Erlotinib	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 22112541]
HepG2	IC₅₀	0.12 μM Compound: ZD 1839	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 23245570]
HepG2	IC₅₀	0.12 μM Compound: Erlotinib	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 23962660]
HepG2	IC₅₀	0.12 μM Compound: Erlotinib	Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 24144854]
HepG2	IC₅₀	0.12 μM Compound: Erlotinib	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 24607998]
HepG2	IC₅₀	0.12 μM Compound: Erlotinib	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 24630412]
HepG2	IC₅₀	0.1 μM Compound: Erlotinib	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 25172421]
HepG2	IC₅₀	0.12 μM Compound: Erlotinib	Antiproliferative activity against human HepG2 cells after 12 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 12 hrs by MTT assay	[PMID: 26652482]
HepG2	IC₅₀	5.8 μM Compound: Erlotinib	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 26896708]
HepG2	IC₅₀	25 μM Compound: Erlotinib	Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 24 hrs by spectrophotometry Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 24 hrs by spectrophotometry	[PMID: 28487127]
HepG2	IC₅₀	25 μM Compound: Erlotinib	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 30047410]
HepG2	IC₅₀	25.01 μM Compound: Erlotinib	Cytotoxicity against human HepG2 cells after 3 days by MTT assay Cytotoxicity against human HepG2 cells after 3 days by MTT assay	[PMID: 30337229]
HepG2	IC₅₀	25 μM Compound: Erlotinib	Antiproliferative activity against human HepG2 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay	[PMID: 31022583]
HepG2	IC₅₀	11.57 μM Compound: Erlotinib	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31546197]
HepG2	IC₅₀	28.8 μM Compound: Erlotinib	Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay	[PMID: 31671308]
HepG2	IC₅₀	6.73 μM Compound: Erlotinib	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by SRB assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by SRB assay	[PMID: 32361329]
HepG2	IC₅₀	8.19 μM Compound: Erlotinib	Antitumor activity against human HepG2 cells assessed as inhibition of cell viability by MTT assay Antitumor activity against human HepG2 cells assessed as inhibition of cell viability by MTT assay	[PMID: 33065442]
HepG2	IC₅₀	10.23 μM Compound: Erlotinib	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 33423463]
HepG2	IC₅₀	17.68 μM Compound: Erlotinib	Anticancer activity against human HepG2 cells assessed as cell growth inhibition measured by MTT assay Anticancer activity against human HepG2 cells assessed as cell growth inhibition measured by MTT assay	[PMID: 34015505]
HepG2	IC₅₀	10.17 μM Compound: Erlotinib	Cytotoxicity against human HepG2 cells measured after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells measured after 24 hrs by MTT assay	[PMID: 34363937]
HepG2	IC₅₀	9.76 μM Compound: 3a; Erlotinib	Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34416665]
HS27	IC₅₀	>10000 nM Compound: 2	Cytotoxicity against human HS27 cells after 72 hrs by SRB assay Cytotoxicity against human HS27 cells after 72 hrs by SRB assay	[PMID: 19888761]
Hs-578T	IC₅₀	>100 μM Compound: Erlotinib	Antiproliferative activity against human Hs578T cells after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human Hs578T cells after 72 hrs by CellTiter-Glo assay	[PMID: 26599532]
HT-29	IC₅₀	100 μM Compound: 3, Tarceva	Cytotoxicity against human HT-29 cells after 4 days by propidium iodide staining-based fluorometric analysis Cytotoxicity against human HT-29 cells after 4 days by propidium iodide staining-based fluorometric analysis	[PMID: 22169601]
HT-29	IC₅₀	2.98 μM Compound: 4	Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation under normoxia conditions after 72 hrs by SRB assay Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation under normoxia conditions after 72 hrs by SRB assay	[PMID: 25468044]
HT-29	IC₅₀	4.37 μM Compound: 4	Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation under hypoxia conditions after 72 hrs by SRB assay Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation under hypoxia conditions after 72 hrs by SRB assay	[PMID: 25468044]
HT-29	IC₅₀	0.03 μM Compound: Erlotinib	Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 48 hrs by propidium iodide staining based fluorometer assay Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 48 hrs by propidium iodide staining based fluorometer assay	[PMID: 27010345]
HT-29	EC₅₀	>1000 nM Compound: Erlotinib	Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 27010810]
HT-29	IC₅₀	0.02 μM Compound: Erlotinib	Antiproliferative activity human HT-29 cells after 48 hrs by propidium iodide staining-based fluorescence assay Antiproliferative activity human HT-29 cells after 48 hrs by propidium iodide staining-based fluorescence assay	[PMID: 29407956]
HT-29	IC₅₀	>20 μM Compound: Erlotinib	Anticancer activity against human HT-29 cells assessed as reduction in cell viability after 96 hrs by MTT assay Anticancer activity against human HT-29 cells assessed as reduction in cell viability after 96 hrs by MTT assay	[PMID: 29549841]
HT-29	IC₅₀	0.05 μM Compound: 1	Antiproliferative activity against human HT-29 cells after 48 hrs by propidium iodide fluorescence assay Antiproliferative activity against human HT-29 cells after 48 hrs by propidium iodide fluorescence assay	[PMID: 30744932]
HT-29	IC₅₀	0.02 μM Compound: ERL	Cytotoxicity against human HT-29 cells by MTT assay Cytotoxicity against human HT-29 cells by MTT assay	[PMID: 31129455]
HT-29	IC₅₀	4.63 μM Compound: Erlotinib	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 33479688]
HT-29	IC₅₀	30 nM Compound: Erlotinib	Antiproliferative activity against human HT-29 cells by MTT assay Antiproliferative activity against human HT-29 cells by MTT assay	[PMID: 37122549]
HT-29	IC₅₀	30 nM Compound: Erlotinib	Antiproliferative activity against human HT-29 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells incubated for 48 hrs by MTT assay	[PMID: 39026636]
Huh-7	EC₅₀	0.5 μM Compound: Erlotinib	Antiviral activity against Hepatitis C virus J6/JFH electroporated in human Huh7.5 cells assessed as inhibition of intracellular infectivity drug treated every 24 hrs for 72 hrs measured 72 hrs post electroporation by luciferase reporter gene assay Antiviral activity against Hepatitis C virus J6/JFH electroporated in human Huh7.5 cells assessed as inhibition of intracellular infectivity drug treated every 24 hrs for 72 hrs measured 72 hrs post electroporation by luciferase reporter gene assay	[PMID: 25822739]
Huh-7	EC₅₀	0.5 μM Compound: Erlotinib	Antiviral activity against Hepatitis C virus J6/JFH infected in human Huh7.5 cells assessed as inhibition of extracellular infectivity drug treated every 24 hrs for 72 hrs measured after 72 hrs by luciferase reporter gene assay Antiviral activity against Hepatitis C virus J6/JFH infected in human Huh7.5 cells assessed as inhibition of extracellular infectivity drug treated every 24 hrs for 72 hrs measured after 72 hrs by luciferase reporter gene assay	[PMID: 25822739]
Huh-7	EC₅₀	0.5 μM Compound: Erlotinib	Antiviral activity against Hepatitis C virus J6/JFH infected in human Huh7.5 cells assessed as inhibition of viral replication measured after 72 hrs by luciferase reporter gene assay Antiviral activity against Hepatitis C virus J6/JFH infected in human Huh7.5 cells assessed as inhibition of viral replication measured after 72 hrs by luciferase reporter gene assay	[PMID: 25822739]
Huh-7	IC₅₀	25 μM Compound: Erlotinib	Antiproliferative activity against human HuH7 cells after 48 hrs by MTT assay Antiproliferative activity against human HuH7 cells after 48 hrs by MTT assay	[PMID: 29057042]
Huh-7	CC₅₀	>10 μM Compound: Erlotinib	Cytotoxicity against human HuH7 cells assessed as reduction in cell viability incubated for 48 hrs by alamar blue reagent based cell viability assay Cytotoxicity against human HuH7 cells assessed as reduction in cell viability incubated for 48 hrs by alamar blue reagent based cell viability assay	[PMID: 31757682]
Huh-7	EC₅₀	1.22 μM Compound: Erlotinib	Antiviral activity against Dengue virus 2 infected in human HuH7 cells incubated for 48 hrs by luciferase reporter gene assay Antiviral activity against Dengue virus 2 infected in human HuH7 cells incubated for 48 hrs by luciferase reporter gene assay	[PMID: 31757682]
Huh-7	CC₅₀	>20 μM Compound: Erlotinib	Cytotoxicity against DENV-2 New Guinea C infected human Huh-7 cells assessed as reduction in cell viability preincubated for 1 hr followed by viral infection and measured after 48 hrs by Alamar blue assay Cytotoxicity against DENV-2 New Guinea C infected human Huh-7 cells assessed as reduction in cell viability preincubated for 1 hr followed by viral infection and measured after 48 hrs by Alamar blue assay	[PMID: 33497888]
Huh-7.5	CC₅₀	>5 μM Compound: 23	Cytotoxicity against human Huh7.5 cells Cytotoxicity against human Huh7.5 cells	[PMID: 33539089]
HUVEC	IC₅₀	165.2 nM Compound: Erlotinib	Cytotoxicity against HUVEC Cytotoxicity against HUVEC	[PMID: 24890652]
Jurkat	IC₅₀	2 μM Compound: erlotinib	Growth inhibition of human Jurkat cells after 24 hrs Growth inhibition of human Jurkat cells after 24 hrs	[PMID: 17178722]
Jurkat	IC₅₀	12.07 μM Compound: Erlotinib	Antiproliferative activity aganist human Jurkat cells incubated for 72 hrs by MTT assay Antiproliferative activity aganist human Jurkat cells incubated for 72 hrs by MTT assay	[PMID: 31493743]
K562	IC₅₀	55 μM Compound: Erlotinib	Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 72 hrs by Cell Titer Glo luminescent cell viability assay Antiproliferative activity against human K562 cells assessed as inhibition of cell growth incubated for 72 hrs by Cell Titer Glo luminescent cell viability assay	[PMID: 27614407]
K562	IC₅₀	3.29 μM Compound: Erlotinib	Antiproliferative activity against human K562 cells assessed as cell growth inhibition at 10 uM relative to control Antiproliferative activity against human K562 cells assessed as cell growth inhibition at 10 uM relative to control	[PMID: 33271454]
KB	IC₅₀	0.019 μM Compound: Erlotinib, Tarceva	Inhibition of EGF-stimulated autophosphorylation of EGFR in human KB cells incubated for 1 hr prior to EGF challenge measured after 6 mins by ELISA Inhibition of EGF-stimulated autophosphorylation of EGFR in human KB cells incubated for 1 hr prior to EGF challenge measured after 6 mins by ELISA	[PMID: 24411123]
KB	IC₅₀	5 μM Compound: 2	Antiproliferative activity against human KB cells expressing EGFR and Src after 48 hrs by SRB assay Antiproliferative activity against human KB cells expressing EGFR and Src after 48 hrs by SRB assay	[PMID: 26188620]
KB	IC₅₀	13.01 μM Compound: Erlotinib	Cytotoxicity against human KB cells after 3 days by MTT assay Cytotoxicity against human KB cells after 3 days by MTT assay	[PMID: 30337229]
KB	IC₅₀	0.019 μM Compound: Erlotinib	Inhibition of EGFR in human KB cells assessed as reduction in EGF-stimulated EGFR phosphorylation preincubated for 1 hr followed by EGF stimulation and measured after 6 mins by ELISA Inhibition of EGFR in human KB cells assessed as reduction in EGF-stimulated EGFR phosphorylation preincubated for 1 hr followed by EGF stimulation and measured after 6 mins by ELISA	[PMID: 32139324]
L02	IC₅₀	18.5 μM Compound: Erlotinib	Cytotoxicity against human LO2 cells after 48 hrs by MTT assay Cytotoxicity against human LO2 cells after 48 hrs by MTT assay	[PMID: 26896708]
L02	IC₅₀	7.25 μM Compound: Erlotinib	Cytotoxicity against human L0-2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human L0-2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32402937]
L3.6pl	IC₅₀	4 μM Compound: Erlotinib	Growth inhibition of human L3.6PL cells after 72 hrs by CCK-8 assay Growth inhibition of human L3.6PL cells after 72 hrs by CCK-8 assay	[PMID: 26547690]
Leukemia cell	IC₅₀	2 μM Compound: erlotinib	Growth inhibition of JAK2 V617F mutant expressing human erythroleukemia cells after 24 hrs Growth inhibition of JAK2 V617F mutant expressing human erythroleukemia cells after 24 hrs	[PMID: 17178722]
Leukemia cell	IC₅₀	2 μM Compound: erlotinib	Growth inhibition of mouse erythroleukemia cells after 24 hrs Growth inhibition of mouse erythroleukemia cells after 24 hrs	[PMID: 17178722]
LNCaP	IC₅₀	18.35 μM Compound: erlotinib	Antiproliferative activity against human LNCAP cells Antiproliferative activity against human LNCAP cells	[PMID: 20143778]
LNCaP	IC₅₀	6.63 μM Compound: 3, Tarceva	Cytotoxicity against human LNCAP cells after 4 days by propidium iodide staining-based fluorometric analysis Cytotoxicity against human LNCAP cells after 4 days by propidium iodide staining-based fluorometric analysis	[PMID: 22169601]
LoVo	IC₅₀	0.077 μM Compound: 2	Inhibition of wild type EGFR phosphorylation in human LoVo cells after 2 hrs by fluorescence assay Inhibition of wild type EGFR phosphorylation in human LoVo cells after 2 hrs by fluorescence assay	[PMID: 23930994]
LoVo	IC₅₀	8.61 μM Compound: Erlotinib	Antiproliferative activity against human LoVo cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Antiproliferative activity against human LoVo cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 33423463]
MCF7	IC₅₀	0.02 μM Compound: Erlotinib	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 19914835]
MCF7	IC₅₀	0.01 μM Compound: Erlotinib	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 19914837]
MCF7	IC₅₀	0.02 μM Compound: Erlotinib	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 20005116]
MCF7	IC₅₀	>20 μM Compound: erlotinib	Antiproliferative activity against human MCF7 cells after hrs by ATP content assay Antiproliferative activity against human MCF7 cells after hrs by ATP content assay	[PMID: 20143778]
MCF7	IC₅₀	0.02 μM Compound: Erlotinib	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 20594859]
MCF7	IC₅₀	0.02 μM Compound: Erlotinib	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 20627597]
MCF7	IC₅₀	0.02 μM Compound: Erlotinib	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 21802290]
MCF7	IC₅₀	100 μM Compound: 3, Tarceva	Cytotoxicity against human MCF7 cells after 4 days by propidium iodide staining-based fluorometric analysis Cytotoxicity against human MCF7 cells after 4 days by propidium iodide staining-based fluorometric analysis	[PMID: 22169601]
MCF7	IC₅₀	0.02 μM Compound: Erlotinib	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 22277588]
MCF7	IC₅₀	0.07 μM Compound: Tarceva	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 22361272]
MCF7	IC₅₀	4.03 μg/mL Compound: Erlotinib	Antiproliferative activity against human MCF7 cells after 24 to 48 hrs by WST1 assay Antiproliferative activity against human MCF7 cells after 24 to 48 hrs by WST1 assay	[PMID: 22901387]
MCF7	IC₅₀	8.97 μM Compound: Erlotinib	Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 22985957]
MCF7	IC₅₀	0.02 μM Compound: Erlotinib	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 23245802]
MCF7	GI₅₀	0.08 μM Compound: Erlotinib	Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 23391364]
MCF7	IC₅₀	1.2 nM Compound: Erlotinib	Cytotoxicity against human ER-positive MCF7 cells Cytotoxicity against human ER-positive MCF7 cells	[PMID: 24890652]
MCF7	IC₅₀	0.1 μM Compound: Erlotinib	Antiproliferative activity against human MCF7 cells after 12 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 12 hrs by MTT assay	[PMID: 26652482]
MCF7	IC₅₀	0.02 μM Compound: Erlotinib	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by propidium iodide staining based fluorometer assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by propidium iodide staining based fluorometer assay	[PMID: 27010345]
MCF7	IC₅₀	0.08 μM Compound: Erlotinib	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 28988624]
MCF7	IC₅₀	0.03 μM Compound: Erlotinib	Antiproliferative activity human MCF7 cells after 48 hrs by propidium iodide staining-based fluorescence assay Antiproliferative activity human MCF7 cells after 48 hrs by propidium iodide staining-based fluorescence assay	[PMID: 29407956]
MCF7	IC₅₀	>20 μM Compound: Erlotinib	Anticancer activity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by MTT assay Anticancer activity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by MTT assay	[PMID: 29549841]
MCF7	IC₅₀	20 μM Compound: Erlotinib	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 30047410]
MCF7	IC₅₀	2.32 μM Compound: Erlotinib	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 30503938]
MCF7	IC₅₀	12.42 μM Compound: Erlotinib	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 30562699]
MCF7	IC₅₀	0.03 μM Compound: ERL	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 31129455]
MCF7	IC₅₀	1.88 μM Compound: Erlotinib	Inhibition of EGFR-TK in human MCF7 cells overexpressing EGFR incubated for 18 to 24 hrs by kinase assay Inhibition of EGFR-TK in human MCF7 cells overexpressing EGFR incubated for 18 to 24 hrs by kinase assay	[PMID: 31416740]
MCF7	IC₅₀	8.24 μM Compound: Erlotinib	Antiproliferative activity aganist human MCF7 cells incubated for 72 hrs by MTT assay Antiproliferative activity aganist human MCF7 cells incubated for 72 hrs by MTT assay	[PMID: 31493743]
MCF7	IC₅₀	11.57 μM Compound: Erlotinib	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31546197]
MCF7	IC₅₀	11.7 μM Compound: Erlotinib	Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay	[PMID: 31671308]
MCF7	IC₅₀	2.7 μM Compound: Erlotinib	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability in presence of SAHA by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability in presence of SAHA by MTT assay	[PMID: 32320239]
MCF7	IC₅₀	3.11 μM Compound: Erlotinib	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by SRB assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by SRB assay	[PMID: 32361329]
MCF7	IC₅₀	4.15 μM Compound: Erlotinib	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 3 days by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 3 days by MTT assay	[PMID: 32828424]
MCF7	IC₅₀	4.16 μM Compound: Erlotinib	Antitumor activity against human MCF7 cells assessed as inhibition of cell viability by MTT assay Antitumor activity against human MCF7 cells assessed as inhibition of cell viability by MTT assay	[PMID: 33065442]
MCF7	IC₅₀	>30 μM Compound: Erlotinib	Antiproliferative activity against human MCF-7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF-7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 33479688]
MCF7	IC₅₀	11.18 μM Compound: Erlotinib	Cytotoxicity against human MCF7 cells incubated for 2 to 4 hrs by MTT assay Cytotoxicity against human MCF7 cells incubated for 2 to 4 hrs by MTT assay	[PMID: 33771586]
MCF7	IC₅₀	4.1 μM Compound: Erlotinib	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition and measured after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition and measured after 72 hrs by SRB assay	[PMID: 34000484]
MCF7	IC₅₀	11.57 μM Compound: Erlotinib	Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured by MTT assay Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured by MTT assay	[PMID: 34015505]
MCF7	IC₅₀	12.4 μM Compound: Erlotinib	Cytotoxicity against human MCF7 cells measured after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells measured after 24 hrs by MTT assay	[PMID: 34363937]
MCF7	IC₅₀	>50 μM Compound: 3a; Erlotinib	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34416665]
MCF7	EC₅₀	2.83 μM Compound: Erlotinib	Cytotoxicity against human MCF7 cells measured after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells measured after 48 hrs by MTT assay	[PMID: 35569690]
MCF7	IC₅₀	40 nM Compound: Erlotinib	Antiproliferative activity against human MCF7 cells by MTT assay Antiproliferative activity against human MCF7 cells by MTT assay	[PMID: 37122549]
MCF7	IC₅₀	32.29 μM Compound: Erlotinib	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 38107169]
MCF7	IC₅₀	40 nM Compound: Erlotinib	Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay	[PMID: 39026636]
MCF7	IC₅₀	>10 μM Compound: Erlotinib	Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay	[PMID: 39026650]
MCF7	IC₅₀	0.22 μM Compound: Erlotinib	Antiproliferative activity against Homo sapiens (human) MCF-7 cells overexpressing EGFR assessed as inhibition of cell survival after 48 hr by MTT assay Antiproliferative activity against Homo sapiens (human) MCF-7 cells overexpressing EGFR assessed as inhibition of cell survival after 48 hr by MTT assay	10.1007/s00044-012-0093-z
MDA-MB-231	IC₅₀	>20 μM Compound: erlotinib	Antiproliferative activity against human MDA-MB-231 cells after hrs by ATP content assay Antiproliferative activity against human MDA-MB-231 cells after hrs by ATP content assay	[PMID: 20143778]
MDA-MB-231	IC₅₀	34.5 μM Compound: 3, Tarceva	Cytotoxicity against human MDA231 cells after 4 days by propidium iodide staining-based fluorometric analysis Cytotoxicity against human MDA231 cells after 4 days by propidium iodide staining-based fluorometric analysis	[PMID: 22169601]
MDA-MB-231	IC₅₀	438.5 nM Compound: Erlotinib	Cytotoxicity against human triple negative MDA-MB-231 cells Cytotoxicity against human triple negative MDA-MB-231 cells	[PMID: 24890652]
MDA-MB-231	EC₅₀	>1000 nM Compound: Erlotinib	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 27010810]
MDA-MB-231	IC₅₀	30.12 μM Compound: Erlotinib	Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay	[PMID: 28923383]
MDA-MB-231	IC₅₀	33.46 μM Compound: Erlotinib	Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay	[PMID: 28923383]
MDA-MB-231	IC₅₀	55.51 μM Compound: Erlotinib	Antiproliferative activity against human MDA-MB-231 cells incubated for 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells incubated for 24 hrs by MTT assay	[PMID: 28923383]
MDA-MB-231	IC₅₀	14.74 μM Compound: 1; Erlo	Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 30108891]
MDA-MB-231	IC₅₀	0.05 μM Compound: Erlotinib	Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 30562699]
MDA-MB-231	IC₅₀	8.3 μM Compound: Erlotinib	Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay	[PMID: 31671308]
MDA-MB-231	IC₅₀	0.07182 μM Compound: Erlotinib	Effect on Bcl2 expression in human MDA-MB-231 cells Effect on Bcl2 expression in human MDA-MB-231 cells	[PMID: 32739648]
MDA-MB-231	IC₅₀	0.48 μM Compound: Erlotinib	Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	[PMID: 32739648]
MDA-MB-231	IC₅₀	0.48 μM Compound: Erlotinib	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	[PMID: 32739648]
MDA-MB-231	IC₅₀	11.0418 μM Compound: Erlotinib	Effect on Bax expression in human MDA-MB-231 cells Effect on Bax expression in human MDA-MB-231 cells	[PMID: 32739648]
MDA-MB-231	IC₅₀	4.56 μM Compound: Erlotinib	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 32739648]
MDA-MB-231	IC₅₀	15.51 μM Compound: Erlotinib	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth by MTT assay	[PMID: 32949719]
MDA-MB-231	IC₅₀	5.46 μM Compound: Erlotinib	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 33479688]
MDA-MB-231	IC₅₀	2.54 μM Compound: Erlotinib	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37122544]
MDA-MB-231	IC₅₀	>10 μM Compound: Erlotinib	Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay	[PMID: 39026650]
MDA-MB-435	IC₅₀	622.1 nM Compound: Erlotinib	Cytotoxicity against human MDA-MB-435 cells Cytotoxicity against human MDA-MB-435 cells	[PMID: 24890652]
MDA-MB-435	IC₅₀	7.05 μM Compound: Erlotinib	Antiproliferative activity against human MDA-MB-435 cells assessed as cell growth inhibition at 10 uM relative to control Antiproliferative activity against human MDA-MB-435 cells assessed as cell growth inhibition at 10 uM relative to control	[PMID: 33271454]
MDA-MB-468	IC₅₀	11.4 μM Compound: erlotinib	Antiproliferative activity against human MDA-MB-468 cells Antiproliferative activity against human MDA-MB-468 cells	[PMID: 20143778]
MDA-MB-468	IC₅₀	235.2 nM Compound: Erlotinib	Cytotoxicity against human triple negative MDA-MB-468 cells Cytotoxicity against human triple negative MDA-MB-468 cells	[PMID: 24890652]
MEXF276L	IC₅₀	18.6 μM Compound: 3, Tarceva	Cytotoxicity against human MEXF 276L cells after 4 days by propidium iodide staining-based fluorometric analysis Cytotoxicity against human MEXF 276L cells after 4 days by propidium iodide staining-based fluorometric analysis	[PMID: 22169601]
MGC-803	IC₅₀	10.78 μM Compound: 3a; Erlotinib	Antiproliferative activity against human MGC-803 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human MGC-803 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34416665]
MIA PaCa-2	IC₅₀	82.47 μM Compound: Erlotinib	Cytotoxicity against human MIAPaCa2 cells after 4 to 5 days by MTT assay Cytotoxicity against human MIAPaCa2 cells after 4 to 5 days by MTT assay	[PMID: 20466555]
MIA PaCa-2	IC₅₀	>10 μM Compound: Erlotinib	Growth inhibition of human MIAPaCa2 cells after 72 hrs by CCK-8 assay Growth inhibition of human MIAPaCa2 cells after 72 hrs by CCK-8 assay	[PMID: 26547690]
MIA PaCa-2	IC₅₀	0.03 μM Compound: Erlotinib	Antiproliferative activity against human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 48 hrs by propidium iodide staining based fluorometer assay Antiproliferative activity against human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 48 hrs by propidium iodide staining based fluorometer assay	[PMID: 27010345]
MIA PaCa-2	EC₅₀	27 μM Compound: Erlotinib	Antiproliferative activity against human MIA PaCa-2 cells assessed as cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human MIA PaCa-2 cells assessed as cell viability measured after 72 hrs by MTT assay	[PMID: 28105281]
MIA PaCa-2	IC₅₀	0.03 μM Compound: Erlotinib	Antiproliferative activity human MIAPaCa2 cells after 48 hrs by propidium iodide staining-based fluorescence assay Antiproliferative activity human MIAPaCa2 cells after 48 hrs by propidium iodide staining-based fluorescence assay	[PMID: 29407956]
MIA PaCa-2	IC₅₀	0.04 μM Compound: 1	Antiproliferative activity against human MIAPaCa2 cells after 48 hrs by propidium iodide fluorescence assay Antiproliferative activity against human MIAPaCa2 cells after 48 hrs by propidium iodide fluorescence assay	[PMID: 30744932]
MIA PaCa-2	IC₅₀	0.04 μM Compound: ERL	Cytotoxicity against human MIAPaCa2 cells by MTT assay Cytotoxicity against human MIAPaCa2 cells by MTT assay	[PMID: 31129455]
MKN-45	IC₅₀	76.7 μM Compound: 3, Tarceva	Cytotoxicity against human MKN45 cells after 4 days by propidium iodide staining-based fluorometric analysis Cytotoxicity against human MKN45 cells after 4 days by propidium iodide staining-based fluorometric analysis	[PMID: 22169601]
MRC5	IC₅₀	5.8 μM Compound: Erlotinib	Antiproliferative activity against human MRC5 cells after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human MRC5 cells after 72 hrs by CellTiter-Glo assay	[PMID: 26599532]
NCI-H1299	IC₅₀	>=21.1 μM Compound: Chemical Probe: Erlotinib	Antiproliferative activity against human NCI-H1299 cells assessed as reduction in cell proliferation measured after 72 hrs by celltiter-glo assay Antiproliferative activity against human NCI-H1299 cells assessed as reduction in cell proliferation measured after 72 hrs by celltiter-glo assay	[PMID: 20571069]
NCI-H1299	IC₅₀	3.33 μM Compound: Erlotinib	Antiproliferative activity against human NCI-H1299 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human NCI-H1299 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 32739648]
NCI-H1299	IC₅₀	28.92 μM Compound: Erlotinib	Antiproliferative activity against human NCI-H1299 cells assessed as reduction in cell growth by MTT assay Antiproliferative activity against human NCI-H1299 cells assessed as reduction in cell growth by MTT assay	[PMID: 32949719]
NCI-H1299	IC₅₀	3.05 μM Compound: Erlotinib	Antiproliferative activity against human H1299 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human H1299 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 33479688]
NCI-H1563	IC₅₀	8.17 μM Compound: Erlotinib	Antiproliferative activity against human NCI-H1563 cells assessed as inhibition of cell growth Antiproliferative activity against human NCI-H1563 cells assessed as inhibition of cell growth	[PMID: 36509365]
NCI-H1650	IC₅₀	>50 μM Compound: 3a; Erlotinib	Antiproliferative activity against human NCI-H1650 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1650 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34416665]
NCI-H1650	IC₅₀	40 μM Compound: Erlotinib	Antiproliferative activity against human NCI-H1650 cells assessed as reduction in cell growth incubated for 72 hrs by cell-titer glo assay Antiproliferative activity against human NCI-H1650 cells assessed as reduction in cell growth incubated for 72 hrs by cell-titer glo assay	[PMID: 38889607]
NCI-H1975	IC₅₀	>1000 nM Compound: 2	Cytotoxicity against human NCI-H1975 cells after 24 hrs by MTT assay Cytotoxicity against human NCI-H1975 cells after 24 hrs by MTT assay	[PMID: 19888761]
NCI-H1975	IC₅₀	7.6 μM Compound: 2	Inhibition of EGFR L858R/T970M double mutant phosphorylation in human NCI-H1975 cells after 2 hrs by fluorescence assay Inhibition of EGFR L858R/T970M double mutant phosphorylation in human NCI-H1975 cells after 2 hrs by fluorescence assay	[PMID: 23930994]
NCI-H1975	IC₅₀	7.6 μM Compound: 2	Inhibition of EGFR L858R/T790M double mutant phosphorylation in human NCI-H1975 cells after 2 hrs by fluorescence assay Inhibition of EGFR L858R/T790M double mutant phosphorylation in human NCI-H1975 cells after 2 hrs by fluorescence assay	[PMID: 23930994]
NCI-H1975	IC₅₀	6.9 μM Compound: 2	Antiproliferative activity against human NCI-H1975 cells expressing EGFR T790M mutant after 72 hrs by SRB assay Antiproliferative activity against human NCI-H1975 cells expressing EGFR T790M mutant after 72 hrs by SRB assay	[PMID: 24183742]
NCI-H1975	IC₅₀	5.51 μM Compound: Erlotinib, Tarceva	Cytotoxicity against human NCI-H1975 cells expressing EGFR L858R/T790M mutant after 72 hrs by MTT assay Cytotoxicity against human NCI-H1975 cells expressing EGFR L858R/T790M mutant after 72 hrs by MTT assay	[PMID: 24411123]
NCI-H1975	IC₅₀	7.06 μM Compound: 2	Antiproliferative activity against gefitinib-resistant human NCI-H1975 cells assessed as growth inhibition after 72 hrs by SRB assay Antiproliferative activity against gefitinib-resistant human NCI-H1975 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 24565969]
NCI-H1975	IC₅₀	7.498 μM Compound: Erlotinib	Cytotoxicity against human NCI-H1975 cells after 48 hrs by MTT assay Cytotoxicity against human NCI-H1975 cells after 48 hrs by MTT assay	[PMID: 24900830]
NCI-H1975	IC₅₀	9 μM Compound: 3	Inhibition of EGFR L858R/T790M double mutant autophosphorylation in human NCI-H1975 cells after 2 hrs by sandwich ELISA Inhibition of EGFR L858R/T790M double mutant autophosphorylation in human NCI-H1975 cells after 2 hrs by sandwich ELISA	[PMID: 26756222]
NCI-H1975	EC₅₀	>1000 nM Compound: Erlotinib	Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant after 72 hrs by MTT assay	[PMID: 27010810]
NCI-H1975	IC₅₀	5.51 μM Compound: Tarceva	Cytotoxicity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 27524310]
NCI-H1975	IC₅₀	10 μM Compound: Erlotinib	Antiproliferative activity against human NCI-H1975 cells harbouring EGFR L858R/T790M double mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells harbouring EGFR L858R/T790M double mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31446247]
NCI-H1975	IC₅₀	47.6 μM Compound: 2	Antiproliferative activity against human NCI-H1975 cells expressing EGFR L858R/T790M mutant assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human NCI-H1975 cells expressing EGFR L858R/T790M mutant assessed as inhibition of cell growth by MTT assay	[PMID: 31869655]
NCI-H1975	IC₅₀	5.51 μM Compound: Erlotinib	Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutant assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutant assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 32139324]
NCI-H1975	IC₅₀	>20 μM Compound: Erlotinib	Antiproliferative activity against human H1975 cells harboring EGFR L858R/T790M double mutant assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human H1975 cells harboring EGFR L858R/T790M double mutant assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32402937]
NCI-H1975	IC₅₀	13.12 μM Compound: Erlotinib	Antiproliferative activity against human NCI-H1975 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33640672]
NCI-H1975	IC₅₀	25.63 μM Compound: 3a; Erlotinib	Antiproliferative activity against human NCI-H1975 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34416665]
NCI-H1975	IC₅₀	4.67 μM Compound: Erlotinib	Antiproliferative activity against human NCI-H1975 cells harboring T790M mutation assessed as inhibition of cell growth Antiproliferative activity against human NCI-H1975 cells harboring T790M mutation assessed as inhibition of cell growth	[PMID: 36509365]
NCI-H1975	IC₅₀	10.2 μM Compound: Erlotinib	Antiproliferative activity against human NCI-H1975 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human NCI-H1975 cells assessed as inhibition of cell growth by MTT assay	[PMID: 36893627]
NCI-H1975	GI₅₀	>10000 nM Compound: 1	Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutant assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutant assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay	[PMID: 37499291]
NCI-H1975	IC₅₀	37 μM Compound: Erlotinib	Antiproliferative activity against human NCI-H1975 cells assessed as reduction in cell growth incubated for 72 hrs by cell-titer glo assay Antiproliferative activity against human NCI-H1975 cells assessed as reduction in cell growth incubated for 72 hrs by cell-titer glo assay	[PMID: 38889607]
NCI-H1993	IC₅₀	2.043 μM Compound: Erlotinib	Cytotoxicity against human NCI-H1993 cells after 48 hrs by MTT assay Cytotoxicity against human NCI-H1993 cells after 48 hrs by MTT assay	[PMID: 24900830]
NCI-H2122	IC₅₀	1 μM Compound: erlotinib	Antiproliferative activity against human NCI-H2122 cells Antiproliferative activity against human NCI-H2122 cells	[PMID: 20143778]
NCI-H23	IC₅₀	10.6 μM Compound: Chemical Probe: Erlotinib	Antiproliferative activity against human NCI-H23 cells assessed as reduction in cell proliferation measured after 72 hrs by celltiter-glo assay Antiproliferative activity against human NCI-H23 cells assessed as reduction in cell proliferation measured after 72 hrs by celltiter-glo assay	[PMID: 20571069]
NCI-H23	IC₅₀	49.3 μM Compound: Erlotinib	Cytotoxicity against human NCI-H23 cells assessed as reduction in cell viability after 46 hrs by MTT assay Cytotoxicity against human NCI-H23 cells assessed as reduction in cell viability after 46 hrs by MTT assay	[PMID: 29138027]
NCI-H292	IC₅₀	0.5 μM Compound: Chemical Probe: Erlotinib	Antiproliferative activity against human NCI-H292 cells assessed as reduction in cell proliferation measured after 72 hrs by celltiter-glo assay Antiproliferative activity against human NCI-H292 cells assessed as reduction in cell proliferation measured after 72 hrs by celltiter-glo assay	[PMID: 20571069]
NCI-H292	IC₅₀	1 μM Compound: Erlotinib	Cytotoxicity against human NCI-H292 cells after 72 hrs by SRB assay Cytotoxicity against human NCI-H292 cells after 72 hrs by SRB assay	[PMID: 25215856]
NCI-H292	EC₅₀	31 nM Compound: erlotinib	Antiproliferative activity against human NCI-H292 cells expressing wild type EGFR after 72 hrs by luminescence assay Antiproliferative activity against human NCI-H292 cells expressing wild type EGFR after 72 hrs by luminescence assay	[PMID: 26455919]
NCI-H292	IC₅₀	6.3 nM Compound: erlotinib	Inhibition of EGFR phosphorylation in human NCI-H292 cells preincubated for 1 hr followed by stimulation with EGF for 8 mins by electrochemiluminescent immunoassay Inhibition of EGFR phosphorylation in human NCI-H292 cells preincubated for 1 hr followed by stimulation with EGF for 8 mins by electrochemiluminescent immunoassay	[PMID: 26455919]
NCI-H3255	GI₅₀	458 nM Compound: 1	Antiproliferative activity against human NCI-H3255 cells harboring EGFR L858R mutant assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay Antiproliferative activity against human NCI-H3255 cells harboring EGFR L858R mutant assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay	[PMID: 37499291]
NCI-H358	IC₅₀	6 μM Compound: erlotinib	Antiproliferative activity against human NCI-H358 cells after hrs by ATP content assay Antiproliferative activity against human NCI-H358 cells after hrs by ATP content assay	[PMID: 20143778]
NCI-H358	IC₅₀	4.4 μM Compound: Chemical Probe: Erlotinib	Antiproliferative activity against human NCI-H358 cells assessed as reduction in cell proliferation measured after 72 hrs by celltiter-glo assay Antiproliferative activity against human NCI-H358 cells assessed as reduction in cell proliferation measured after 72 hrs by celltiter-glo assay	[PMID: 20571069]
NCI-H358	IC₅₀	6.85 μM Compound: Erlotinib	Antiproliferative activity against human NCI-H358 cells assessed as viable cells after 48 hrs by CCK8 assay Antiproliferative activity against human NCI-H358 cells assessed as viable cells after 48 hrs by CCK8 assay	[PMID: 26879314]
NCI-H358	IC₅₀	3.91 μM Compound: Erlotinib	Antiproliferative activity against human NCI-H358 cells assessed as reduction in cell viability after 48 hrs by cck8 assay Antiproliferative activity against human NCI-H358 cells assessed as reduction in cell viability after 48 hrs by cck8 assay	[PMID: 27234887]
NCI-H460	IC₅₀	8.2 μM Compound: erlotinib	Antiproliferative activity against human H460 cells after hrs by ATP content assay Antiproliferative activity against human H460 cells after hrs by ATP content assay	[PMID: 20143778]
NCI-H460	IC₅₀	19.9 μM Compound: Chemical Probe: Erlotinib	Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell proliferation measured after 72 hrs by celltiter-glo assay Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell proliferation measured after 72 hrs by celltiter-glo assay	[PMID: 20571069]
NCI-H460	IC₅₀	74.3 μM Compound: 3, Tarceva	Cytotoxicity against human H460 cells after 4 days by propidium iodide staining-based fluorometric analysis Cytotoxicity against human H460 cells after 4 days by propidium iodide staining-based fluorometric analysis	[PMID: 22169601]
NCI-H460	IC₅₀	9.5 μM Compound: Erlotinib	Cytotoxicity against human H460 cells after 72 hrs by SRB assay Cytotoxicity against human H460 cells after 72 hrs by SRB assay	[PMID: 25215856]
NCI-H460	IC₅₀	0.04 μM Compound: Erlotinib	Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell growth incubated for 48 hrs by propidium iodide staining based fluorometer assay Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell growth incubated for 48 hrs by propidium iodide staining based fluorometer assay	[PMID: 27010345]
NCI-H460	IC₅₀	0.02 μM Compound: 1	Antiproliferative activity against human NCI-H460 cells after 48 hrs by propidium iodide fluorescence assay Antiproliferative activity against human NCI-H460 cells after 48 hrs by propidium iodide fluorescence assay	[PMID: 30744932]
NCI-H460	IC₅₀	24.6 μM Compound: Erlotinib	Antiproliferative activity against human H460 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human H460 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31078412]
NCI-H460	IC₅₀	0.02 μM Compound: ERL	Cytotoxicity against human H460 cells by MTT assay Cytotoxicity against human H460 cells by MTT assay	[PMID: 31129455]
NCI-H460	IC₅₀	25.32 μM Compound: Erlotinib	Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell growth by MTT assay Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell growth by MTT assay	[PMID: 32949719]
NCI-H460	IC₅₀	12.86 μM Compound: 3a; Erlotinib	Antiproliferative activity against human NCI-H460 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human NCI-H460 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34416665]
NCI-H460	IC₅₀	10.2 μM Compound: Erlotinib	Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell growth by MTT assay	[PMID: 36893627]
NCI-H460	IC₅₀	12.84 μM Compound: Erlotinib	Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell growth incubated for 48 hrs in presence of 10-hydroxyl-evodiamine by MTT assay Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell growth incubated for 48 hrs in presence of 10-hydroxyl-evodiamine by MTT assay	[PMID: 38244939]
NCI-H460	IC₅₀	13.29 μM Compound: Erlotinib	Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38244939]
NCI-H460	IC₅₀	13.44 μM Compound: Erlotinib	Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell growth incubated for 48 hrs in presence of evodiamine by MTT assay Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell growth incubated for 48 hrs in presence of evodiamine by MTT assay	[PMID: 38244939]
NCI-H661	IC₅₀	12.71 μM Compound: Erlotinib	Cytotoxicity against human NCI-H661 cells after 4 to 5 days by MTT assay Cytotoxicity against human NCI-H661 cells after 4 to 5 days by MTT assay	[PMID: 20466555]
NCI-H727	IC₅₀	>6240 nM Compound: Erlotinib	Antiproliferative activity against human NCI-H727 cells after 48 hrs by MTT assay Antiproliferative activity against human NCI-H727 cells after 48 hrs by MTT assay	[PMID: 29057042]
NCI-N87	IC₅₀	5200 nM Compound: Erlotinib	Inhibition of ErbB2 intracellular phosphorylation in human N87 cells by ELISA Inhibition of ErbB2 intracellular phosphorylation in human N87 cells by ELISA	[PMID: 20346655]
NCI-N87	IC₅₀	>10 μM Compound: Erlotinib, Tarceva	Cytotoxicity against human NCI-N87 cells expressing HER2 after 72 hrs by MTT assay Cytotoxicity against human NCI-N87 cells expressing HER2 after 72 hrs by MTT assay	[PMID: 24411123]
NCI-N87	IC₅₀	>10 μM Compound: Tarceva	Cytotoxicity against human NCI-N87 cells overexpressing HER2 assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human NCI-N87 cells overexpressing HER2 assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 27524310]
NCI-N87	IC₅₀	>10 μM Compound: Erlotinib	Antiproliferative activity against human NCI-N87 cells overexpressing HER2 assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human NCI-N87 cells overexpressing HER2 assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 32139324]
NIH3T3	IC₅₀	19.3 nM Compound: erlotinib	Inhibition of EGF stimulated human erbB1 autophosphorylation in NIH3T3 cells Inhibition of EGF stimulated human erbB1 autophosphorylation in NIH3T3 cells	[PMID: 16480284]
NIH3T3	IC₅₀	>10 μM Compound: Erlotinib	Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by MTT assay Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by MTT assay	[PMID: 24900830]
NIH3T3	IC₅₀	7 μM Compound: CP-358,774	Antiproliferative activity against raf-transformed mouse NIH3T3 cells assessed as inhibition of cell viability Antiproliferative activity against raf-transformed mouse NIH3T3 cells assessed as inhibition of cell viability	[PMID: 9354447]
OVCAR-3	IC₅₀	100 μM Compound: 3, Tarceva	Cytotoxicity against human OVCAR3 cells after 4 days by propidium iodide staining-based fluorometric analysis Cytotoxicity against human OVCAR3 cells after 4 days by propidium iodide staining-based fluorometric analysis	[PMID: 22169601]
OVCAR-3	IC₅₀	4.6 μM Compound: Erlotinib	Antiproliferative activity against human OVCAR3 cells after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human OVCAR3 cells after 72 hrs by CellTiter-Glo assay	[PMID: 26599532]
PANC-1	IC₅₀	>100 μM Compound: Erlotinib	Cytotoxicity against human PANC1 cells after 4 to 5 days by MTT assay Cytotoxicity against human PANC1 cells after 4 to 5 days by MTT assay	[PMID: 20466555]
PANC-1	IC₅₀	75.8 μM Compound: 3, Tarceva	Cytotoxicity against human PANC1 cells after 4 days by propidium iodide staining-based fluorometric analysis Cytotoxicity against human PANC1 cells after 4 days by propidium iodide staining-based fluorometric analysis	[PMID: 22169601]
PANC-1	IC₅₀	3.1 μM Compound: Erlotinib	Growth inhibition of human PANC1 cells after 72 hrs by CCK-8 assay Growth inhibition of human PANC1 cells after 72 hrs by CCK-8 assay	[PMID: 26547690]
PANC-1	IC₅₀	0.02 μM Compound: Erlotinib	Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell growth incubated for 48 hrs by propidium iodide staining based fluorometer assay Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell growth incubated for 48 hrs by propidium iodide staining based fluorometer assay	[PMID: 27010345]
PANC-1	IC₅₀	0.06 μM Compound: 1	Antiproliferative activity against human PANC1 cells after 48 hrs by propidium iodide fluorescence assay Antiproliferative activity against human PANC1 cells after 48 hrs by propidium iodide fluorescence assay	[PMID: 30744932]
PANC-1	IC₅₀	0.02 μM Compound: ERL	Cytotoxicity against human PANC1 cells by MTT assay Cytotoxicity against human PANC1 cells by MTT assay	[PMID: 31129455]
PANC-1	IC₅₀	20 μM Compound: Erlotinib	Cytotoxicity against human PANC-1 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay Cytotoxicity against human PANC-1 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 32736230]
PANC-1	IC₅₀	30 nM Compound: Erlotinib	Antiproliferative activity against human PANC-1 cells by MTT assay Antiproliferative activity against human PANC-1 cells by MTT assay	[PMID: 37122549]
PANC-1	IC₅₀	30 nM Compound: Erlotinib	Antiproliferative activity against human PANC-1 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human PANC-1 cells incubated for 48 hrs by MTT assay	[PMID: 39026636]
Panel NCI-60 (60 carcinoma cell lines)	GI₅₀	7.29 μM Compound: Erlotinib	Anticancer activity against human Panel NCI-60 (60 carcinoma cell lines) cells assessed as cell growth inhibition incubated for 48 hrs by sulforhodamine B assay Anticancer activity against human Panel NCI-60 (60 carcinoma cell lines) cells assessed as cell growth inhibition incubated for 48 hrs by sulforhodamine B assay	[PMID: 31881454]
Panel NCI-60 cells	GI₅₀	7.29 μM Compound: Erlotinib	Anticancer activity against human Panel NCI-60 (60 carcinoma cell lines) cells assessed as cell growth inhibition incubated for 48 hrs by sulforhodamine B assay Anticancer activity against human Panel NCI-60 (60 carcinoma cell lines) cells assessed as cell growth inhibition incubated for 48 hrs by sulforhodamine B assay	[PMID: 31881454]
PBMC	IC₅₀	39.32 μM Compound: Erlotinib	Cytotoxicity against human PBMC cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human PBMC cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31493743]
PBMC	IC₅₀	20.46 μM Compound: Erlotinib	Cytotoxicity against human PBMC cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human PBMC cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31546197]
PC-3	IC₅₀	36.76 μM Compound: Erlotinib	Cytotoxicity against human PC3 cells after 4 to 5 days by MTT assay Cytotoxicity against human PC3 cells after 4 to 5 days by MTT assay	[PMID: 20466555]
PC-3	IC₅₀	0.02 μM Compound: Erlotinib	Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 48 hrs by propidium iodide staining based fluorometer assay Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 48 hrs by propidium iodide staining based fluorometer assay	[PMID: 27010345]
PC-3	EC₅₀	>1000 nM Compound: Erlotinib	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 27010810]
PC-3	IC₅₀	0.03 μM Compound: Erlotinib	Antiproliferative activity human PC3 cells after 48 hrs by propidium iodide staining-based fluorescence assay Antiproliferative activity human PC3 cells after 48 hrs by propidium iodide staining-based fluorescence assay	[PMID: 29407956]
PC-3	IC₅₀	0.02 μM Compound: ERL	Cytotoxicity against human PC3 cells by MTT assay Cytotoxicity against human PC3 cells by MTT assay	[PMID: 31129455]
PC-3	IC₅₀	11.57 μM Compound: Erlotinib	Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31546197]
PC-3	IC₅₀	7 μM Compound: Erlotinib	Antiproliferative activity against human PC3 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human PC3 cells incubated for 48 hrs by MTT assay	[PMID: 31671308]
PC-3	IC₅₀	26.85 μM Compound: Erlotinib	Anticancer activity against human PC-3 cells assessed as cell growth inhibition measured by MTT assay Anticancer activity against human PC-3 cells assessed as cell growth inhibition measured by MTT assay	[PMID: 34015505]
PC-3	IC₅₀	9.53 μM Compound: 3a; Erlotinib	Antiproliferative activity against human PC-3 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human PC-3 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34416665]
PC-3M	IC₅₀	17.2 μM Compound: 3, Tarceva	Cytotoxicity against human PC3M cells after 4 days by propidium iodide staining-based fluorometric analysis Cytotoxicity against human PC3M cells after 4 days by propidium iodide staining-based fluorometric analysis	[PMID: 22169601]
PC-9	IC₅₀	1.36 μM Compound: Erlotinib	Inhibition of EGFR phosphorylation in human PC9 cells after 24 hrs by by Western blot analysis Inhibition of EGFR phosphorylation in human PC9 cells after 24 hrs by by Western blot analysis	[PMID: 22980218]
PC-9	IC₅₀	0.0059 μM Compound: 2	Inhibition of EGFR exon 19 deletion activating mutant phosphorylation in human PC9 cells after 2 hrs by fluorescence assay Inhibition of EGFR exon 19 deletion activating mutant phosphorylation in human PC9 cells after 2 hrs by fluorescence assay	[PMID: 23930994]
PC-9	IC₅₀	0.07 μM Compound: Erlotinib	Antiproliferative activity against human PC9 cells after 96 hrs by Sytox green marker based fluorescence analysis Antiproliferative activity against human PC9 cells after 96 hrs by Sytox green marker based fluorescence analysis	[PMID: 26599532]
PC-9	IC₅₀	11 nM Compound: 3	Inhibition of EGFR deletion mutant autophosphorylation in human PC9 cells after 2 hrs by sandwich ELISA Inhibition of EGFR deletion mutant autophosphorylation in human PC9 cells after 2 hrs by sandwich ELISA	[PMID: 26756222]
PC-9	IC₅₀	<0.1 μM Compound: Erlotinib	Antiproliferative activity against human PC9 cells measured for 96 hrs by sytox green dye staining based proliferation assay Antiproliferative activity against human PC9 cells measured for 96 hrs by sytox green dye staining based proliferation assay	[PMID: 27614407]
PC-9	IC₅₀	0.1 μM Compound: Erlotinib	Antiproliferative activity against human PC9 cells harbouring EGFR delE746-A750 mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human PC9 cells harbouring EGFR delE746-A750 mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31446247]
PC-9	IC₅₀	>50 μM Compound: Erlotinib	Antiproliferative activity against human PC9 cells harboring EGFRdel19 mutant assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human PC9 cells harboring EGFRdel19 mutant assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32402937]
PC-9	IC₅₀	1.72 μM Compound: Erlotinib	Antiproliferative activity against human PC-9 cells assessed as inhibition of cell growth incubated for 48 hrs in presence of 10-hydroxyl-evodiamine by MTT assay Antiproliferative activity against human PC-9 cells assessed as inhibition of cell growth incubated for 48 hrs in presence of 10-hydroxyl-evodiamine by MTT assay	[PMID: 38244939]
PC-9	IC₅₀	1.8 μM Compound: Erlotinib	Antiproliferative activity against human PC-9 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human PC-9 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38244939]
PC-9	IC₅₀	2.37 μM Compound: Erlotinib	Antiproliferative activity against human PC-9 cells assessed as inhibition of cell growth incubated for 48 hrs in presence of evodiamine by MTT assay Antiproliferative activity against human PC-9 cells assessed as inhibition of cell growth incubated for 48 hrs in presence of evodiamine by MTT assay	[PMID: 38244939]
RKO	IC₅₀	100 μM Compound: 3, Tarceva	Cytotoxicity against human RKO cells after 4 days by propidium iodide staining-based fluorometric analysis Cytotoxicity against human RKO cells after 4 days by propidium iodide staining-based fluorometric analysis	[PMID: 22169601]
SAOS-2	IC₅₀	21 μM Compound: 3, Tarceva	Cytotoxicity against human Saos2 cells after 4 days by propidium iodide staining-based fluorometric analysis Cytotoxicity against human Saos2 cells after 4 days by propidium iodide staining-based fluorometric analysis	[PMID: 22169601]
SCC-15	IC₅₀	1.94 μM Compound: erlotinib	Antiproliferative activity against human SCC15 cells Antiproliferative activity against human SCC15 cells	[PMID: 20143778]
SCC-25	IC₅₀	3.34 μM Compound: erlotinib	Antiproliferative activity against human SCC25 cells Antiproliferative activity against human SCC25 cells	[PMID: 20143778]
SF-539	IC₅₀	83.1 μM Compound: 1	Inhibition of PDGFRbeta phosphorylation in human SF539 cells after 10 mins by FLISA Inhibition of PDGFRbeta phosphorylation in human SF539 cells after 10 mins by FLISA	[PMID: 20403700]
SF-539	IC₅₀	83.1 μM Compound: 1	Inhibition of PDGFRbeta tyrosine kinase activity in PDGF-BB-stimulated human SF-539 cells after 60 mins by ELISA Inhibition of PDGFRbeta tyrosine kinase activity in PDGF-BB-stimulated human SF-539 cells after 60 mins by ELISA	[PMID: 22204741]
SF-539	IC₅₀	12.2 μM Compound: Erlotinib	Inhibition of PDGFRbeta in human SF539 cells pretreated for 60 mins measured after 1 hr by ELISA Inhibition of PDGFRbeta in human SF539 cells pretreated for 60 mins measured after 1 hr by ELISA	[PMID: 22739090]
SF-539	IC₅₀	12.2 μM Compound: 2	Inhibition of PDGF-BB-induced PDGFR beta phosphorylation in human SF539 cells overexpressing PDGFR beta pretreated for 60 mins prior to PDGF-BB addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis Inhibition of PDGF-BB-induced PDGFR beta phosphorylation in human SF539 cells overexpressing PDGFR beta pretreated for 60 mins prior to PDGF-BB addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis	[PMID: 23375090]
SF-539	IC₅₀	12.2 μM Compound: Erlotinib	Inhibition of PDGFRbeta in human SF539 cells assessed as inhibition of PDGFR-BB-induced tyrosine phosphorylation incubated for 60 mins prior to EGF-activation measured 10 mins by ELISA Inhibition of PDGFRbeta in human SF539 cells assessed as inhibition of PDGFR-BB-induced tyrosine phosphorylation incubated for 60 mins prior to EGF-activation measured 10 mins by ELISA	[PMID: 23434139]
Sf9	IC₅₀	0.03 μM Compound: Erlotinib	Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA	[PMID: 19914835]
Sf9	IC₅₀	0.16 μM Compound: Erlotinib	Inhibition of human cloned HER2 autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA Inhibition of human cloned HER2 autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA	[PMID: 19914835]
Sf9	IC₅₀	0.02 μM Compound: Erlotinib	Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA Inhibition of cloned EGFR autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA	[PMID: 19914837]
Sf9	IC₅₀	0.12 μM Compound: Erlotinib	Inhibition of human cloned HER2 autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA Inhibition of human cloned HER2 autophosphorylation expressed in baculovirus-infected Sf9 cells by solid-phase ELISA	[PMID: 19914837]
Sf9	IC₅₀	0.02 μM Compound: Erlotinib	Inhibition of recombinant EGFR expressed in Sf9-baculovirus system by ELISA Inhibition of recombinant EGFR expressed in Sf9-baculovirus system by ELISA	[PMID: 20005116]
Sf9	IC₅₀	0.16 μM Compound: Erlotinib	Inhibition of human recombinant HER2 expressed in Sf9-baculovirus system by ELISA Inhibition of human recombinant HER2 expressed in Sf9-baculovirus system by ELISA	[PMID: 20005116]
Sf9	IC₅₀	0.03 μM Compound: Erlotinib	Inhibition of human recombinant His6x-tagged EGFR autophosphorylation expressed in Sf9 cells after 1 hr by ELISA Inhibition of human recombinant His6x-tagged EGFR autophosphorylation expressed in Sf9 cells after 1 hr by ELISA	[PMID: 20594859]
Sf9	IC₅₀	0.16 μM Compound: Erlotinib	Inhibition of human recombinant His6x-tagged HER2 autophosphorylation expressed in Sf9 cells after 1 hr by ELISA Inhibition of human recombinant His6x-tagged HER2 autophosphorylation expressed in Sf9 cells after 1 hr by ELISA	[PMID: 20594859]
Sf9	IC₅₀	0.03 μM Compound: Erlotinib	Inhibition of histidine-tagged recombinant EGFR autophosphorylation expressed in Sf9 cells by solid-phase ELISA Inhibition of histidine-tagged recombinant EGFR autophosphorylation expressed in Sf9 cells by solid-phase ELISA	[PMID: 20627597]
Sf9	IC₅₀	0.03 μM Compound: Erlotinib, ZD-1839	Inhibition of recombinant EGFR expressed in baculovirus infected Sf9 cells after 1 hr by DELFIA/time-resolved fluorimetry assay Inhibition of recombinant EGFR expressed in baculovirus infected Sf9 cells after 1 hr by DELFIA/time-resolved fluorimetry assay	[PMID: 21763148]
Sf9	IC₅₀	0.03 μM Compound: Erlotinib	Inhibition of His-tagged EGFR expressed in insect Sf9 cells after 1 hr by time-resolved fluorimetric analysis Inhibition of His-tagged EGFR expressed in insect Sf9 cells after 1 hr by time-resolved fluorimetric analysis	[PMID: 21816517]
Sf9	IC₅₀	0.03 μM Compound: Erlotinib	Inhibition of EGFR expressed in baculovirus infected Sf9 cells assessed as inhibition of autophosphorylation preincubated for 10 mins measured after 1 hr by DELFIA/Time-Resolved Fluorometry Inhibition of EGFR expressed in baculovirus infected Sf9 cells assessed as inhibition of autophosphorylation preincubated for 10 mins measured after 1 hr by DELFIA/Time-Resolved Fluorometry	[PMID: 22112541]
Sf9	IC₅₀	0.03 μM Compound: Erlotinib	Inhibition of autophosphorylation of recombinant His-tagged EGFR expressed in baculovirus infected Sf9 cells after 1 hr by DELFIA/time-resolved fluorimetry assay Inhibition of autophosphorylation of recombinant His-tagged EGFR expressed in baculovirus infected Sf9 cells after 1 hr by DELFIA/time-resolved fluorimetry assay	[PMID: 22277588]
Sf9	IC₅₀	0.03 μM Compound: Tarceva	Inhibition of histidine-tagged human recombinant cytoplasmic domain of EGFR expressed in baculovirus infected insect Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis Inhibition of histidine-tagged human recombinant cytoplasmic domain of EGFR expressed in baculovirus infected insect Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis	[PMID: 22361272]
Sf9	IC₅₀	0.14 μM Compound: Tarceva	Inhibition of histidine-tagged human recombinant cytoplasmic domain of HER2 expressed in baculovirus infected insect Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis Inhibition of histidine-tagged human recombinant cytoplasmic domain of HER2 expressed in baculovirus infected insect Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis	[PMID: 22361272]
Sf9	IC₅₀	0.03 μM Compound: ZD 1839	Inhibition of EGFR cytoplasmic domain (amino acids 645 to 1186) (unknown origin) expressed in Sf9 cells assessed as reduction in enzyme autophosphorylation by DELFIA time resolved fluorometry Inhibition of EGFR cytoplasmic domain (amino acids 645 to 1186) (unknown origin) expressed in Sf9 cells assessed as reduction in enzyme autophosphorylation by DELFIA time resolved fluorometry	[PMID: 23245570]
Sf9	IC₅₀	0.16 μM Compound: Erlotinib	Inhibition of human HER2 cytoplasmic domain (amino acids 676 to 1245) expressed in Sf9 cells by DELFIA time resolved fluorometry Inhibition of human HER2 cytoplasmic domain (amino acids 676 to 1245) expressed in Sf9 cells by DELFIA time resolved fluorometry	[PMID: 23245802]
Sf9	IC₅₀	0.03 μM Compound: Erlotinib	Inhibition of recombinant EGFR kinase cytoplasmic domain (unknown origin) expressed in baculovirus expression vector-infected insect sf9 cells assessed as level of autophosphorylation after 10 mins by DELFIA/time-resolved fluorometry Inhibition of recombinant EGFR kinase cytoplasmic domain (unknown origin) expressed in baculovirus expression vector-infected insect sf9 cells assessed as level of autophosphorylation after 10 mins by DELFIA/time-resolved fluorometry	[PMID: 23962660]
Sf9	IC₅₀	0.032 μM Compound: Erlotinib	Inhibition of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) autophosphorylation expressed in baculovirus infected insect Sf9 cells preincubated for 10 mins followed by ATP-MgCl2 addition measured after 1 hr by fluorometric analysis Inhibition of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) autophosphorylation expressed in baculovirus infected insect Sf9 cells preincubated for 10 mins followed by ATP-MgCl2 addition measured after 1 hr by fluorometric analysis	[PMID: 24144854]
Sf9	IC₅₀	0.032 μM Compound: Erlotinib	Inhibition of autophosphorylation of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) expressed in Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis Inhibition of autophosphorylation of recombinant EGFR cytoplasmic domain (645 to 1186) (unknown origin) expressed in Sf9 cells after 1 hr by DELFIA/time-resolved fluorometric analysis	[PMID: 24607998]
Sf9	IC₅₀	0.032 μM Compound: Erlotinib	Inhibition of autophosphorylation of EGFR cytoplasmic domain (amino acids 645 to 1186) (unknown origin) expressed in Sf9 cells after 1 hr by time-resolved fluorometry Inhibition of autophosphorylation of EGFR cytoplasmic domain (amino acids 645 to 1186) (unknown origin) expressed in Sf9 cells after 1 hr by time-resolved fluorometry	[PMID: 24630412]
Sf9	IC₅₀	0.16 μM Compound: Erlotinib	Inhibition of autophosphorylation of human HER2 cytoplasmic domain (amino acids 676 to 1245) (unknown origin) expressed in Sf9 cells after 1 hr by time-resolved fluorometry Inhibition of autophosphorylation of human HER2 cytoplasmic domain (amino acids 676 to 1245) (unknown origin) expressed in Sf9 cells after 1 hr by time-resolved fluorometry	[PMID: 24630412]
Sf9	IC₅₀	0.03 μM Compound: Erlotinib	Inhibition of histidine-tagged recombinant EGFR cytoplasmic domain (amino acids 645-1186) (unknown origin) expressed in Sf9 cells assessed as reduction in enzyme autophosphorylation by DELFIA/time-resolved fluorometry Inhibition of histidine-tagged recombinant EGFR cytoplasmic domain (amino acids 645-1186) (unknown origin) expressed in Sf9 cells assessed as reduction in enzyme autophosphorylation by DELFIA/time-resolved fluorometry	[PMID: 25172421]
Sf9	IC₅₀	0.2 μM Compound: Erlotinib	Inhibition of histidine-tagged recombinant HER2 (unknown origin) expressed in Sf9 cells assessed as reduction in enzyme autophosphorylation by DELFIA/time-resolved fluorometry Inhibition of histidine-tagged recombinant HER2 (unknown origin) expressed in Sf9 cells assessed as reduction in enzyme autophosphorylation by DELFIA/time-resolved fluorometry	[PMID: 25172421]
Sf9	IC₅₀	0.06 μM Compound: 1	Inhibition of His6-tagged EGFR cytoplasmic domain (645 to 1186 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells after 10 mins by DELFIA/time-resolved fluorometry Inhibition of His6-tagged EGFR cytoplasmic domain (645 to 1186 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells after 10 mins by DELFIA/time-resolved fluorometry	[PMID: 30744932]
Sf9	IC₅₀	>30 μM Compound: Erlotinib	Inhibition of recombinant human N-terminal GST-tagged HER2 (676 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide as substrate incubated for 1 hr by ADP-Glo assay Inhibition of recombinant human N-terminal GST-tagged HER2 (676 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide as substrate incubated for 1 hr by ADP-Glo assay	[PMID: 31493743]
Sf9	IC₅₀	>30 μM Compound: Erlotinib	Inhibition of recombinant human N-terminal GST-tagged INSR (1011 to end residues) expressed in baculovirus infected Sf9 insect cells using Axltide as substrate incubated for 1 hr by ADP-Glo assay Inhibition of recombinant human N-terminal GST-tagged INSR (1011 to end residues) expressed in baculovirus infected Sf9 insect cells using Axltide as substrate incubated for 1 hr by ADP-Glo assay	[PMID: 31493743]
Sf9	IC₅₀	>30 μM Compound: Erlotinib	Inhibition of recombinant human N-terminal GST-tagged PDGFRbeta (557 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide as substrate incubated for 1 hr by ADP-Glo assay Inhibition of recombinant human N-terminal GST-tagged PDGFRbeta (557 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide as substrate incubated for 1 hr by ADP-Glo assay	[PMID: 31493743]
Sf9	IC₅₀	>30 μM Compound: Erlotinib	Inhibition of recombinant human N-terminal His-tagged IGF1R (960 to end residues) expressed in baculovirus infected Sf9 insect cells using IGF1Rtide as substrate incubated for 1 hr by ADP-Glo assay Inhibition of recombinant human N-terminal His-tagged IGF1R (960 to end residues) expressed in baculovirus infected Sf9 insect cells using IGF1Rtide as substrate incubated for 1 hr by ADP-Glo assay	[PMID: 31493743]
Sf9	IC₅₀	0.05 μM Compound: Erlotinib	Inhibition of recombinant human N-terminal GST-tagged EGFR (695 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide as substrate incubated for 1 hr by ADP-Glo assay Inhibition of recombinant human N-terminal GST-tagged EGFR (695 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide as substrate incubated for 1 hr by ADP-Glo assay	[PMID: 31493743]
Sf9	IC₅₀	2.59 μM Compound: Erlotinib	Inhibition of recombinant human N-terminal GST-tagged HER4 (682 to 993 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide as substrate incubated for 1 hr by ADP-Glo assay Inhibition of recombinant human N-terminal GST-tagged HER4 (682 to 993 residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide as substrate incubated for 1 hr by ADP-Glo assay	[PMID: 31493743]
Sf9	IC₅₀	5.06 μM Compound: Erlotinib	Inhibition of recombinant human N-terminal GST-tagged KDR (789 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide as substrate incubated for 1 hr by ADP-Glo assay Inhibition of recombinant human N-terminal GST-tagged KDR (789 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide as substrate incubated for 1 hr by ADP-Glo assay	[PMID: 31493743]
Sf9	IC₅₀	8.12 μM Compound: Erlotinib	Inhibition of recombinant human N-terminal GST-tagged PDGFRalpha (550 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide as substrate incubated for 1 hr by ADP-Glo assay Inhibition of recombinant human N-terminal GST-tagged PDGFRalpha (550 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide as substrate incubated for 1 hr by ADP-Glo assay	[PMID: 31493743]
Sf9	IC₅₀	0.34 μM Compound: Erlotinib	Inhibition of autophosphorylation of His6-tagged EGFR cytoplasmic domain (unknown origin) expressed in Sf9 cells by DELFIA time resolved fluorometry Inhibition of autophosphorylation of His6-tagged EGFR cytoplasmic domain (unknown origin) expressed in Sf9 cells by DELFIA time resolved fluorometry	10.1007/s00044-012-0093-z
SK-BR-3	IC₅₀	0.868 μg/mL Compound: 2 (Tarceva)	Inhibition of SKBR-3 cell proliferation Inhibition of SKBR-3 cell proliferation	[PMID: 12270171]
SK-BR-3	IC₅₀	>1000 nM Compound: 2	Cytotoxicity against human SKBR3 cells after 72 hrs by SRB assay Cytotoxicity against human SKBR3 cells after 72 hrs by SRB assay	[PMID: 19888761]
SK-BR-3	IC₅₀	1.56 μM Compound: erlotinib	Antiproliferative activity against human SK-BR-3 cells after hrs by ATP content assay Antiproliferative activity against human SK-BR-3 cells after hrs by ATP content assay	[PMID: 20143778]
SK-BR-3	IC₅₀	>100 μM Compound: Erlotinib	Antiproliferative activity against human SKBR3 cells after 72 hrs by CellTiter blue assay Antiproliferative activity against human SKBR3 cells after 72 hrs by CellTiter blue assay	[PMID: 26599532]
SK-BR-3	IC₅₀	3.98 μM Compound: Erlotinib	Cytotoxicity against human SKBR3 cells after 24 hrs by MTT assay Cytotoxicity against human SKBR3 cells after 24 hrs by MTT assay	[PMID: 30562699]
SK-BR-3	IC₅₀	49.33 μM Compound: Erlotinib	Antiproliferative activity against human SKBR3 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human SKBR3 cells incubated for 48 hrs by MTT assay	[PMID: 31671308]
SK-BR-3	IC₅₀	15 μM Compound: 6	Cytotoxicity against human SKBR3 cells by Alamar Blue assay Cytotoxicity against human SKBR3 cells by Alamar Blue assay	10.1039/C2MD00317A
SK-HEP1	IC₅₀	10.37 μM Compound: erlotinib	Antiproliferative activity against human SKHEP1 cells after hrs by ATP content assay Antiproliferative activity against human SKHEP1 cells after hrs by ATP content assay	[PMID: 20143778]
SK-LU-1	IC₅₀	99.76 μM Compound: Erlotinib	Cytotoxicity against human SK-LU-1 cells after 3 days by MTT assay Cytotoxicity against human SK-LU-1 cells after 3 days by MTT assay	[PMID: 30337229]
SK-MEL-28	IC₅₀	38.65 μM Compound: Erlotinib	Antiproliferative activity against human SK-MEL-28 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human SK-MEL-28 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 38107169]
SK-OV-3	IC₅₀	61.78 μM Compound: Erlotinib	Antiproliferative activity against human SKOV3 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human SKOV3 cells incubated for 48 hrs by MTT assay	[PMID: 31671308]
SK-OV-3	IC₅₀	31 μM Compound: 6	Cytotoxicity against human SKOV3 cells by Alamar Blue assay Cytotoxicity against human SKOV3 cells by Alamar Blue assay	10.1039/C2MD00317A
SW480	IC₅₀	>100 μM Compound: Erlotinib	Antiproliferative activity against human SW480 cells after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human SW480 cells after 72 hrs by CellTiter-Glo assay	[PMID: 26599532]
SW480	IC₅₀	22.99 μM Compound: Erlotinib	Antiproliferative activity against human SW480 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human SW480 cells incubated for 48 hrs by MTT assay	[PMID: 31671308]
SW-620	IC₅₀	>5 μg/mL Compound: 2 (Tarceva)	Inhibition of SW-620 cell proliferation Inhibition of SW-620 cell proliferation	[PMID: 12270171]
T-24	IC₅₀	299 nM Compound: erlotinib	Inhibition of ligand stimulated erbB2 autophosphorylation in T24 NIH cells Inhibition of ligand stimulated erbB2 autophosphorylation in T24 NIH cells	[PMID: 16480284]
T-24	IC₅₀	13.9 μM Compound: 3, Tarceva	Cytotoxicity against human BXF T24 cells after 4 days by propidium iodide staining-based fluorometric analysis Cytotoxicity against human BXF T24 cells after 4 days by propidium iodide staining-based fluorometric analysis	[PMID: 22169601]
T47D	IC₅₀	9.8 μM Compound: Erlotinib	Antiproliferative activity against human T47D cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human T47D cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 33479688]
TE-671	IC₅₀	100 μM Compound: 3, Tarceva	Cytotoxicity against human TE671 cells after 4 days by propidium iodide staining-based fluorometric analysis Cytotoxicity against human TE671 cells after 4 days by propidium iodide staining-based fluorometric analysis	[PMID: 22169601]
U-251	IC₅₀	124.7 μM Compound: 1	Inhibition of VEGFR2 phosphorylation in human U251 cells after 10 mins by FLISA Inhibition of VEGFR2 phosphorylation in human U251 cells after 10 mins by FLISA	[PMID: 20403700]
U-251	IC₅₀	124.7 μM Compound: 1	Inhibition of VEGFR2 tyrosine kinase activity in VEGF-stimulated human U251 cells after 60 mins by ELISA Inhibition of VEGFR2 tyrosine kinase activity in VEGF-stimulated human U251 cells after 60 mins by ELISA	[PMID: 22204741]
U-251	IC₅₀	124.7 μM Compound: Erlotinib	Inhibition of VEGFR2 in human U251 cells pretreated for 60 mins measured after 1 hr by ELISA Inhibition of VEGFR2 in human U251 cells pretreated for 60 mins measured after 1 hr by ELISA	[PMID: 22739090]
U-251	IC₅₀	124.7 μM Compound: 2	Inhibition of VEGF-induced VEGFR2 phosphorylation in human U251 cells overexpressing Flk-1 pretreated for 60 mins prior to VEGF addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis Inhibition of VEGF-induced VEGFR2 phosphorylation in human U251 cells overexpressing Flk-1 pretreated for 60 mins prior to VEGF addition measured after 10 mins by phosphotyrosine ELISA cytoblot analysis	[PMID: 23375090]
U-251	IC₅₀	124.7 μM Compound: Erlotinib	Inhibition of VEGFR2 in human U251 cells assessed as inhibition of VEGF-induced tyrosine phosphorylation incubated for 60 mins prior to VEGF-activation measured 10 mins by ELISA Inhibition of VEGFR2 in human U251 cells assessed as inhibition of VEGF-induced tyrosine phosphorylation incubated for 60 mins prior to VEGF-activation measured 10 mins by ELISA	[PMID: 23434139]
U-251	IC₅₀	124.7 nM Compound: Erlotinib	Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA assay Inhibition of VEGFR2 in human U251 cells by phosphotyrosine ELISA assay	[PMID: 24890652]
U-251	IC₅₀	124.7 nM Compound: Erlotinib	Inhibition of VEGFR2 in human U251 cells compound pretreated for 60 min before VEGF stimulation for 10 mins by phosphotyrosine ELISA cytoblot method Inhibition of VEGFR2 in human U251 cells compound pretreated for 60 min before VEGF stimulation for 10 mins by phosphotyrosine ELISA cytoblot method	[PMID: 25882519]
U-87MG ATCC	IC₅₀	31.86 μM Compound: Erlotinib	Antiproliferative activity against human U87 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human U87 cells incubated for 48 hrs by MTT assay	[PMID: 31671308]
U-87MG ATCC	IC₅₀	60.4 μM Compound: 2	Antiproliferative activity against human U-87MG cells harboring wild type EGFR assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human U-87MG cells harboring wild type EGFR assessed as inhibition of cell growth by MTT assay	[PMID: 31869655]
U-937	IC₅₀	9.9 μM Compound: Erlotinib	Antiproliferative activity against human U937 cells after 72 hrs by CellTiter blue assay Antiproliferative activity against human U937 cells after 72 hrs by CellTiter blue assay	[PMID: 26599532]
Vero	CC₅₀	>20 μM Compound: 23	Cytotoxicity against african green monkey Vero cells Cytotoxicity against african green monkey Vero cells	[PMID: 33539089]
Vero	IC₅₀	>6 μM Compound: Erlotinib	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 72 hrs by presto blue reagent assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 72 hrs by presto blue reagent assay	[PMID: 34046625]
WM 266-4	IC₅₀	8.09 μM Compound: Erlotinib	Antiproliferative activity against human WM266.4 cells after 24 hrs by MTT assay Antiproliferative activity against human WM266.4 cells after 24 hrs by MTT assay	[PMID: 22985957]
WM 266-4	GI₅₀	8.12 μM Compound: Erlotinib	Growth inhibition in human WM266.4 cells after 24 hrs by MTT reduction assay Growth inhibition in human WM266.4 cells after 24 hrs by MTT reduction assay	[PMID: 22985962]
WM 266-4	GI₅₀	8.14 μM Compound: Erlotinib	Antiproliferative activity against human WM266.4 cells assessed as cell viability after 24 hrs by MTT assay Antiproliferative activity against human WM266.4 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 27238841]

In Vitro

Erlotinib (CP-358774) (0.01-10 μM; 5 minutes) potently inhibits human OATP2B1 in MDCKII-OATP2B1 cells, with an IC₅₀ of 0.079 μM^[3].
The uptake of erlotinib (approximately 0.016 μM; 7.5 minutes at pH 7.4 or 5.5) in MDCKII-OATP2B1 cells is significantly higher than that in wild-type MDCKII cells, with a 2.5-fold increase at pH 7.4 and a 3.3-fold increase at pH 5.5, which confirms that erlotinib is a substrate of human OATP2B1^[3].
Erlotinib (25 μM; 15 minutes) is metabolized by recombinant rat CYP3A1 and CYP3A2 into its metabolite OSI-420, with similar formation rates of approximately 0.20 ng/pmol CYP3 per minute^[3].
Erlotinib (5-10 μM) potently inhibits Ephrin A1-induced activation of EGFR and ERK in human gastric cancer cell line NCI-N87^[1].
Erlotinib (5-10 μM; 2 weeks) completely inhibits Ephrin A1-induced anchorage-independent colony formation in the human gastric cancer cell line NCI-N87^[1].
Erlotinib (5-10 μM) significantly inhibits ephrin A1-induced transendothelial migration of human gastric cancer cell line NCI-N87 across human umbilical vein endothelial cell (HUVEC) monolayers^[1].
Erlotinib (5-10 μM) inhibits ephrin A1-induced epithelial-mesenchymal transition (EMT) and EGFR activation in human gastric cancer AGS cells^[1].
Erlotinib (5-10 μM) inhibits Ephrin A1-induced invasion of human gastric cancer AGS cells, with 10 μM achieving nearly complete inhibition^[1].
Erlotinib (0.1-3 μM; 5 days) acts synergistically with the KRAS^G12D inhibitor MRTX1133 (HY-134813; 1-300 nM) to reduce the viability of Lkb1-knockout 634T mouse lung cancer spheroids, but exerts no such effect on Lkb1-intact 634T spheroids; significant synergistic effects are observed at erlotinib concentrations ranging from 100 nM to 3000 nM, with further enhanced efficacy at 1 μM^[2].
Erlotinib (2 μM; 1 h pre-incubation followed by 48 h rhMMP-10 exposure) potently inhibits MMP-10-mediated activation of the EGFR/ERK/GSK-3β/β-catenin signaling pathway and induction of pro-fibrotic markers in HK-2 cells^[4].
The IC₅₀ of Erlotinib (0-50 μM; 72 h) in erlotinib-resistant A549 cells is approximately 10-fold that of parental A549 cells^[5].
Erlotinib (15-30 μM; 6 months) induces the formation of an EGFR-independent drug-resistant phenotype in A549 and SK-LU-1 lung cancer cells, whereas Calu-1 cells do not acquire drug resistance under the same conditions^[5].
In erlotinib-resistant A549 cells, knockdown or knockout of GRHL2, knockdown of HER3, or knockout of E-cadherin all reduce the IC₅₀ of erlotinib, indicating that the GRHL2-HER3 axis and E-cadherin-mediated cell adhesion contribute to EGFR bypass resistance via relatively independent pathways^[5].
Erlotinib (5 μM; 24 h) does not induce apoptosis or autophagic cell death in parental or erlotinib-resistant A549 non-small cell lung cancer cells^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[3]

Cell Line:

Lkb1-intact 634T spheroids; Lkb1-knockout 634T spheroids
Concentration:

0.1-3 μM
Incubation Time:

5 days
Result:

Did not produce significant synergism in Lkb1-intact spheroids.
Produced significant synergistic growth inhibition in Lkb1-knockout spheroids, with Bliss scores of 18.24 and 16.24.
Erlotinib at 1 μM markedly enhanced sensitivity to MRTX1133 in Lkb1-knockout spheroids but had minimal sensitizing activity in Lkb1-intact spheroids.

Cell Proliferation Assay^[6]

Cell Line:

Parental A549 non-small cell lung cancer (NSCLC) cells, erlotinib-resistant (ER) A549 NSCLC cells
Concentration:

15-30 μM (generate ER cells); 0-50 μM (proliferation assay); 25 μM (crystal violet staining comparison)
Incubation Time:

6 months (generate ER cells); 72 h (proliferation assay, crystal violet staining comparison)
Result:

Exhibited a low half-maximal inhibitory concentration (IC₅₀) for erlotinib-induced proliferation inhibition in parental A549 cells.
Showed dramatically increased erlotinib resistance in ER cells, with an IC₅₀ approximately 10-fold higher than parental cells.
Reduced parental cell density when cultured with 25 μM erlotinib for 72 h.
Maintained high ER cell density when cultured with 25 μM erlotinib for 72 h.

Immunofluorescence^[2]

Cell Line:

HK-2
Concentration:

2 μM Erlotinib followed by 100 ng/mL rhMMP-10
Incubation Time:

1 h pretreatment followed by 48 h rhMMP-10 treatment
Result:

Abolished rhMMP-10-induced fibronectin expression and extracellular deposition.

Parmacokinetics

Species	Dose	Route	AUC_0-last	AUC_0-∞	CL/F	T_1/2	MRT	C_max	T_max
Rat^[4]	15.5 mg/kg	p.o.	22079 μg/L·h	22202 μg/L·h	0.327 L/h	3.07 h	5.42 h	2310 μg/L	2 h
Rat^[4]	15.5 mg/kg	p.o.	26165 μg/L·h	26665 μg/L·h	0.204 L/h	4.1 h	6.32 h	2294 μg/L	4 h

In Vivo

Erlotinib (CP-358774) (50 mg/kg; intravenous injection; three times per week; for 6 consecutive weeks) reduces lung metastasis of Ephrin A1-overexpressing gastric cancer cells in SCID mice, decreasing the average lung weight by approximately 60% and the average number of metastatic nodules by approximately 80%^[1].
The systemic exposure of erlotinib (15.5 mg/kg; p.o.; single administration) and its metabolite OSI-420 in male Wistar rats is not significantly altered by human OATP2B1, but human OATP2B1 increases the mean residence time of OSI-420 by approximately 30%^[3].
Erlotinib (40-80 mg/kg/day; oral administration; daily dosing; consecutive 5 days) alleviates MMP-10-mediated renal injury and fibrotic lesions in UUO mice in a dose-dependent manner by inhibiting the EGFR/ERK/GSK-3β/β-catenin signaling cascade^[4].
Erlotinib (25 mg/kg; i.p.; administered daily from Monday to Friday for 4 consecutive weeks) significantly inhibits the growth of parental A549 non-small cell lung cancer xenografts in nude mice^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6 (male, 6-8 weeks old, chronic kidney disease induced by unilateral ureteral obstruction surgery plus hydrodynamic-based delivery of Flag-tagged MMP-10 expression vector)^[5]
Dosage:

40 mg/kg/day; 80 mg/kg/day
Administration:

p.o.; daily; 5 days
Result:

Dose-dependently reduced renal p-EGFR, p-ERK1/2, p-GSK3β and active β-catenin.
Reduced KIM-1 and MMP-7 expression.
Suppressed fibronectin and α-SMA expression and decreased collagen deposition and renal fibrotic lesions.

Animal Model:

002019 (nude, injected subcutaneously with luciferase-expressing parental A549 NSCLC cells)^[6]
Dosage:

25 mg/kg
Administration:

i.p.; daily every Monday through Friday; 4 weeks
Result:

Significantly reduced bioluminescence and tumor weight in parental A549 xenografts.
Did not significantly inhibit the growth of Erlotinib-resistant A549 xenografts, demonstrating in vivo resistance to EGFR inhibition.

Animal Model:

SCID mice (female, 4-5 weeks old) were intravenously inoculated with Ephrin A1-overexpressing NCI-N87 cells (2×10⁶ cells/mouse)^[2]
Dosage:

50 mg/kg
Administration:

i.v.; three times per week; 6 weeks
Result:

Markedly reduced lung weight.
Reduced the number of metastatic nodules in lung sections.
Suppressed Ephrin A1/EGFR-dependent gastric cancer lung metastasis.

Chemical Information

CAS No. 183321-74-6
Appearance Solid
Molecular Weight 393.44
Formula C₂₂H₂₃N₃O₄
Color White to light yellow
SMILES

C#CC1=CC=CC(NC2=NC=NC3=C2C=C(C(OCCOC)=C3)OCCOC)=C1
Synonyms

CP-358774; NSC 718781; OSI-774
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (138)

All Flow CytometryWBIF

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]

2025 Dec 15;10(1):406. PMID: 41392286
Cancer Cell

A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers. [Abstract]

2025 Jul 25:S1535-6108(25)00310-1. PMID: 40780213
Nat Immunol

Group 3 innate lymphoid cells produce the growth factor HB-EGF to protect the intestine from TNF-mediated inflammation. [Abstract]

2022 Feb;23(2):251-261. PMID: 35102343
Cell Res

Three-dimensional bioprinted glioblastoma microenvironments model cellular dependencies and immune interactions. [Abstract]

2020 Oct;30(10):833-853. PMID: 32499560
Bioact Mater

Biomimetic hydrogels with mesoscale collagen architecture for patient-derived tumor organoids culture. [Abstract]

2024 May 11:38:384-398. PMID: 38764448
Bioact Mater

A multifunctional nanotheranostic agent potentiates erlotinib to EGFR wild-type non-small cell lung cancer. [Abstract]

2021 Nov 4;13:312-323. PMID: 35224311
Nat Cell Biol

An EGFR co-amplified lncRNA HELDR promotes glioblastoma malignancy through KAT7-driven gene programs. [Abstract]

2026 Mar 27. PMID: 41896311
Mol Cell

EGFR promotes ALKBH5 nuclear retention to attenuate N6-methyladenosine and protect against ferroptosis in glioblastoma. [Abstract]

2023 Dec 7;83(23):4334-4351.e7. PMID: 37979586
Cancer Res

Osimertinib covalently binds to CD34 and eliminates myeloid leukemia stem/progenitor cells. [Abstract]

2024 Feb 1;84(3):479-492. PMID: 38095536
Mol Cell

ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1. [Abstract]

2022 Jul 7;82(13):2443-2457.e7. PMID: 35613620
Nat Commun

An alternative EGFR activation by patient-derived R252C mutation promotes cancer progression. [Abstract]

2026 Jan 21;17(1):1902. PMID: 41565660
Nat Commun

TMEM25 inhibits monomeric EGFR-mediated STAT3 activation in basal state to suppress triple-negative breast cancer progression. [Abstract]

2023 Apr 24;14(1):2342. PMID: 37095176
Nat Commun

Domain-specific p53 mutants activate EGFR by distinct mechanisms exposing tissue-independent therapeutic vulnerabilities. [Abstract]

2023 Mar 28;14(1):1726. PMID: 36977662
Nat Commun

AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy. [Abstract]

2019 Apr 18;10(1):1812 PMID: 31000705
Cell Death Differ

PD-L2 drives resistance to EGFR-TKIs: dynamic changes of the tumor immune environment and targeted therapy. [Abstract]

2024 Sep;31(9):1140-1156. PMID: 38816578
Acta Pharm Sin B

2025 Dec 29.
Sci Transl Med

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]

2018 Jul 18;10(450):eaaq1093. PMID: 30021885
J Clin Invest

IL-36γ drives skin toxicity induced by EGFR/MEK inhibition and commensal Cutibacterium acnes. [Abstract]

2020 Mar 2;130(3):1417-1430. PMID: 31805013
Biomaterials

Automated discovery of nanomaterials via drug aggregation induced emission. [Abstract]

2022 Oct:289:121800. PMID: 36166893
J Exp Clin Cancer Res

High-throughput drug screening identifies EGFR/MAPK pathway targeting sensitivities in organoid models of ovarian carcinosarcoma. [Abstract]

2026 Jan 6;45(1):32. PMID: 41495830
J Exp Clin Cancer Res

Dual inhibition of HERs and PD-1 counteract resistance in KRASG12C-mutant head and neck cancer. [Abstract]

2024 Nov 20;43(1):308. PMID: 39567998
J Exp Clin Cancer Res

The EGFR-HSF1 axis accelerates the tumorigenesis of pancreatic cancer. [Abstract]

2021 Jan 9;40(1):25. PMID: 33422093
Allergy

Amphiregulin Mediates Epithelial Cell-Eosinophil Interactions and Amplifies Inflammation in Chronic Rhinosinusitis With Nasal Polyps. [Abstract]

2025 May;80(5):1335-1347. PMID: 40317745
J Control Release

Macropinocytosis-targeted peptide-docetaxel conjugate for bystander pancreatic cancer treatment. [Abstract]

2024 Dec:376:829-841. PMID: 39491626
Genome Med

The expressed mutational landscape of microsatellite stable colorectal cancers. [Abstract]

2021 Sep 1;13(1):142. PMID: 34470667
Hum Reprod Open

Hypoxia exposure impairs male fertility via inhibiting Septin2-mediated spermatogonial proliferation. [Abstract]

2025 May 14;2025(3):hoaf027. PMID: 40487848
Cell Rep Med

HE4 drives PD-L1 expression in myeloid cells via IFN-γR-JAK-STAT3 signaling to promote tumor immune evasion. [Abstract]

2026 Apr 21;7(4):102691. PMID: 41861828
Cell Rep Med

CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]

2025 Apr 2:102053. PMID: 40187357
Cell Rep Med

Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study. [Abstract]

2023 Feb 21;4(2):100911. PMID: 36657446
Cancer Lett

Identification and characterization of Bufalin as a novel EGFR degrader. [Abstract]

2025 Apr 10:217715. PMID: 40220852
Cell Death Dis

4EBP1 senses extracellular glucose deprivation and initiates cell death signaling in lung cancer. [Abstract]

2022 Dec 27;13(12):1075. PMID: 36575176
Cell Death Dis

ZC3H15 promotes glioblastoma progression through regulating EGFR stability. [Abstract]

2022 Jan 13;13(1):55. PMID: 35027542
Proc Natl Acad Sci U S A

Genome-wide CRISPR screens in spheroid culture reveal that the tumor suppressor LKB1 inhibits growth via the PIKFYVE lipid kinase. [Abstract]

2024 May 21;121(21):e2403685121. PMID: 38743625
J Pharm Anal

Synergistic effects of methyl 2-cyano-3,11-dioxo-18beta-olean-1,-12-dien-30-oate and erlotinib on erlotinib-resistant non-small cell lung cancer cells. [Abstract]

2021 Dec;11(6):799-807. PMID: 35028186
Dev Cell

Non-cell-autonomous tumor promotion in DICER1 cancer predisposition. [Abstract]

2025 Sep 29:S1534-5807(25)00539-8. PMID: 41027427
Int J Biol Macromol

CL4-modified exosomes deliver lncRNA DARS-AS1 siRNA to suppress triple-negative breast cancer progression and attenuate doxorubicin resistance by inhibiting autophagy. [Abstract]

2023 Oct 1:250:126147. PMID: 37544559
Acta Pharmacol Sin

Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway. [Abstract]

2021 Jan;42(1):108-114. PMID: 32398685
EMBO J

Ephrin A1 functions as a ligand of EGFR to promote EMT and metastasis in gastric cancer. [Abstract]

2025 Mar;44(5):1464-1487. PMID: 39838173
NPJ Precis Oncol

High-throughput screening identifies NT-1 that synergizes with MRTX1133 against acquired resistant KRASG12D colorectal cancer. [Abstract]

2026 Apr 8;10(1):211. PMID: 41951768
Cell Syst

Receptor-Driven ERK Pulses Reconfigure MAPK Signaling and Enable Persistence of Drug-Adapted BRAF-Mutant Melanoma Cells. [Abstract]

2020 Nov 18;11(5):478-494.e9. PMID: 33113355
Biomed Pharmacother

Interplay of OATP1A/1B/2B1 uptake transporters and ABCB1 and ABCG2 efflux transporters in the handling of bilirubin and drugs. [Abstract]

2024 Jun:175:116644. PMID: 38692057
Oncogene

AXL activates YAP through the EGFR-LATS1/2 axis and confers resistance to EGFR-targeted drugs in head and neck squamous cell carcinoma. [Abstract]

2023 Sep;42(39):2869-2877. PMID: 37591955
Stem Cell Res Ther

The metabolism of carbamazepine in humans: steric course of the enzymatic hydrolysis of the 10,11-epoxide. [Abstract]

2022 Jun 21;13(1):269. PMID: 3572965
Oncogene

MUC1 triggers lineage plasticity of Her2 positive mammary tumors. [Abstract]

2022 May;41(22):3064-3078. PMID: 35461328
Oncogene

SOX9 is a critical regulator of TSPAN8-mediated metastasis in pancreatic cancer. [Abstract]

2021 Jul;40(30):4884-4893. PMID: 34163029
Oncogene

Epiregulin confers EGFR-TKI resistance via EGFR/ErbB2 heterodimer in non-small cell lung cancer. [Abstract]

2021 Apr;40(14):2596-2609. PMID: 33750895
Oncogene

FOXO3 is essential for CD44 expression in pancreatic cancer cells. [Abstract]

2017 May 11;36(19):2643-2654. PMID: 27893718

Erlotinib purchased from MedChemExpress. Usage Cited in: Oncogene. 2017 May 11;36(19):2643-2654. [Abstract]

Effects of anti-cancer agents Oxaliplatin, Erlotinib (25 μM) and cAMP inducer Forskolin (25 μM) on FOXO3 expression in Panc-1 cells are assessed for 72 h (n=3).
Cell Death Discov

MSLN-mediated activation of EGFR-ERK1/2 signaling drives liver metastasis in breast cancer. [Abstract]

2026 Jan 9;12(1):11. PMID: 41513618
Cell Death Discov

Matrix metalloproteinase-10 promotes kidney fibrosis by transactivating β-catenin signaling. [Abstract]

2025 May 17;11(1):241. PMID: 40382334
Cell Rep

Endocytic activation and exosomal secretion of matriptase stimulate the second wave of EGF signaling to promote skin and breast cancer invasion. [Abstract]

2024 Mar 27;43(4):114002. PMID: 38547126
Cell Rep

Kinetics of RTK activation determine ERK reactivation and resistance to dual BRAF/MEK inhibition in melanoma. [Abstract]

2023 May 29;42(6):112570. PMID: 37252843
Br J Cancer

Fibroblast growth factor signals drive the metastatic behavior in small cell lung cancer. [Abstract]

2025 Dec 13. PMID: 41390896
Br J Cancer

Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinoma. [Abstract]

2023 Feb;128(4):678-690. PMID: 36476658
Ecotoxicol Environ Saf

Protective role of ghrelin against 6PPD-quinone-induced neurotoxicity in zebrafish larvae (Danio rerio) via the GHSR pathway. [Abstract]

2024 Oct 15:285:117031. PMID: 39341137
Ecotoxicol Environ Saf

Hyperphosphorylation of EGFR/ERK signaling facilitates long-term arsenite-induced hepatocytes epithelial-mesenchymal transition and liver fibrosis in sprague-dawley rats. [Abstract]

2023 Jan 1:249:114386. PMID: 36508792
Biomater Adv

Development of a HER1/CP2c dual-targeting biopharmaceutical for HER1-overexpressing head and neck cancer. [Abstract]

2026 Feb 18:183:214782. PMID: 41722284
Anal Chim Acta

Development of novel affinity reagents for detecting protein tyrosine phosphorylation based on superbinder SH2 domain in tumor cells. [Abstract]

2018 Nov 22:1032:138-146. PMID: 30143211

Erlotinib purchased from MedChemExpress. Usage Cited in: Anal Chim Acta. 2018 Nov 22:1032:138-146. [Abstract]

30 min after EGF(100 ng/mL) and EGFP-sSH2(Arg)9 (5 μM) are added into the MDA-MB-468 cell culture medium, Erlotinib is added into the cell culture medium (100 nM), and the picture was collected at 30 min after Erlotinib treatment.
Cell Biol Toxicol

TRPV3 enhances skin keratinocyte proliferation through EGFR-dependent signaling pathways. [Abstract]

2021 Apr;37(2):313-330. PMID: 32535744
J Invest Dermatol

TWEAK/Fn14 Signals Mediate Burn Wound Repair. [Abstract]

2019 Jan;139(1):224-234. PMID: 30081003
Biochem Pharmacol

Pitavastatin overcomes multi-drug resistance in CRC and NSCLC by targeting the NRP1-ZFX axis. [Abstract]

2025 Jul 18:241:117183. PMID: 40684995
Neurobiol Dis

ErbB1-dependent signalling and vesicular trafficking in primary afferent nociceptors associated with hypersensitivity in neuropathic pain. [Abstract]

2020 Aug;142:104961. PMID: 32531343
J Enzyme Inhib Med Chem

Natural product sennoside B disrupts liquid-liquid phase separation of SARS-CoV-2 nucleocapsid protein by inhibiting its RNA-binding activity. [Abstract]

2025 Dec;40(1):2501743. PMID: 40371698
Mar Drugs

New Fusarochromanone Derivatives from the Marine Fungus Fusarium equiseti UBOCC-A-117302. [Abstract]

2024 Sep 28;22(10):444. PMID: 39452852
Virulence

Adaptor complex-mediated trafficking of Newcastle disease virus fusion protein is regulated by the YLMY motif of its cytoplasmic tail. [Abstract]

2022 Dec;13(1):1849-1867. PMID: 36258290
Commun Biol

A small-molecule compound D6 overcomes EGFR-T790M-mediated resistance in non-small cell lung cancer. [Abstract]

2021 Dec 13;4(1):1391. PMID: 34903832
CNS Neurosci Ther

Pharmacological inhibition of epidermal growth factor receptor attenuates intracranial aneurysm formation by modulating the phenotype of vascular smooth muscle cells. [Abstract]

2022 Jan;28(1):64-76. PMID: 34729926
Int J Mol Sci

Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 as a Biomarker for Predicting Response to Erlotinib and Gefitinib in Lung Adenocarcinoma: An Integrative Analysis of Transcriptomic Data of PC-9 and Drug-Resistant PC-9 Cell Lines. [Abstract]

2026 Mar 28;27(7):3092. PMID: 41977278
PLoS Pathog

EGFR-MEK1/2 cascade negatively regulates bactericidal function of bone marrow macrophages in mice with Staphylococcus aureus osteomyelitis. [Abstract]

2024 Aug 5;20(8):e1012437. PMID: 39102432
J Nutr Biochem

High glucose enhances the aggressiveness of lung adenocarcinoma via activating epidermal growth factor receptor/signal transducer and activator of transcription 3 pathways. [Abstract]

2023 Sep:119:109399. PMID: 37271322
Pharmaceuticals (Basel)

Bufadienolides from Chansu Injection Synergistically Enhances the Antitumor Effect of Erlotinib by Inhibiting the KRAS Pathway in Pancreatic Cancer. [Abstract]

2024 Dec 16;17(12):1696. PMID: 39770538
Front Pharmacol

Transcriptomics and Metabolomics Identify Drug Resistance of Dormant Cell in Colorectal Cancer. [Abstract]

2022 Apr 8;13:879751. PMID: 35462906
Front Pharmacol

Topical TWEAK Accelerates Healing of Experimental Burn Wounds in Mice. [Abstract]

2018 Jun 21:9:660. PMID: 29977207

Erlotinib purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2018 Jun 21:9:660. [Abstract]

By Western blotting, the α-SMA and palladin proteins are determined in cells that are pretreated with NF-κB (JSH-23), Wnt/β-catenin (XAV939), EGFR (erlotinib), p38 MAPK (TAK-715), and Smad3 (SIS3) inhibitors and are followed by TWEAK stimulation.
Bioorg Chem

A pomalidomide-based gefitinib PROTAC degrader effectively inhibits lung cancer progression in EGFR-TKIs-acquired resistant models by targeting EGFR degradation and ETFA-mediated ATP generation. [Abstract]

2025 Aug 9:164:108864. PMID: 40815992
Mol Cancer Res

TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations. [Abstract]

2019 Nov;17(11):2233-2243. PMID: 31467113
Cell Rep Methods

RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]

2023 Oct 23;3(10):100599. PMID: 37797618
Mol Oncol

Activation of the EGFR/PI3K/AKT pathway limits the efficacy of trametinib treatment in head and neck cancer. [Abstract]

2023 Dec;17(12):2618-2636. PMID: 37501404
Cell Rep Methods

A hybrid deep forest-based method for predicting synergistic drug combinations. [Abstract]

2023 Feb 21;3(2):100411. PMID: 36936075
Mol Pharm

Combining Gemcitabine-Loaded Macrophage-like Nanoparticles and Erlotinib for Pancreatic Cancer Therapy. [Abstract]

2021 Jul 5;18(7):2495-2506. PMID: 34078087
Mol Oncol

TGF-β transactivates EGFR and facilitates breast cancer migration and invasion through canonical Smad3 and ERK/Sp1 signaling pathways. [Abstract]

2018 Mar;12(3):305-321. PMID: 29215776

Erlotinib purchased from MedChemExpress. Usage Cited in: Mol Oncol. 2018 Mar;12(3):305-321. [Abstract]

Western blot analysis of total and phosphorylated EGFR expression in two breast cancer cells pretreated with different concentration Erlotinib for 4h.
Lung Cancer

HMGB1 Expression Levels Correlate with Response to Immunotherapy in Non-Small Cell Lung Cancer. [Abstract]

2024 May 9:15:55-67. PMID: 38741920
Cancers (Basel)

SCAMP3 Regulates EGFR and Promotes Proliferation and Migration of Triple-Negative Breast Cancer Cells through the Modulation of AKT, ERK, and STAT3 Signaling Pathways. [Abstract]

2022 Jun 5;14(11):2807. PMID: 35681787
ACS Omega

Association Study of OATP1B3 Polymorphisms on Hepatic Uptake and Drug-Drug Interaction In Vitro. [Abstract]

2025 Oct 29;10(44):52562-52575. PMID: 41244417
J Cell Mol Med

PRMT5 promotes epithelial-mesenchymal transition via EGFR-β-catenin axis in pancreatic cancer cells. [Abstract]

2020 Jan;24(2):1969-1979. PMID: 31851779
Adv Ther

2024 Jul 18.
Oncol Rep

Repurposing of a monoamine oxidase A inhibitor‑heptamethine carbocyanine dye conjugate for paclitaxel‑resistant non‑small cell lung cancer. [Abstract]

2021 Mar;45(3):1306-1314. PMID: 33650669
Oncol Rep

Upregulated CTHRC1 promotes human epithelial ovarian cancer invasion through activating EGFR signaling. [Abstract]

2016 Dec;36(6):3588-3596. PMID: 27779718
Mol Divers

Design, synthesis and biological evaluation of thienopyridine derivatives as c-Met kinase inhibitors. [Abstract]

2025 Jun;29(3):2391-2405. PMID: 39356364
Cancer Res Treat

Establishment of Patient-Derived Organoids Using Ascitic or Pleural Fluid from Cancer Patients. [Abstract]

2023 Oct;55(4):1077-1086. PMID: 37309112
Cancer Res Treat

MLL4 Regulates the Progression of Non-Small-Cell Lung Cancer by Regulating the PI3K/AKT/SOX2 Axis. [Abstract]

2023 Jul;55(3):778-803. PMID: 36701842
Bioengineering (Basel)

Precision Oncology for High-Grade Gliomas: A Tumor Organoid Model for Adjuvant Treatment Selection. [Abstract]

2025 Oct 19;12(10):1121. PMID: 41155119
Proteomes

Mass Spectrometry and Pharmacological Approaches to Measuring Cooption and Reciprocal Activation of Receptor Tyrosine Kinases. [Abstract]

2023 Jun 2;11(2):20. PMID: 37368466
Stem Cells

DAPK1 Interacts with the p38 Isoform MAPK14, Preventing Its Nuclear Translocation and Stimulation of Bone Marrow Adipogenesis. [Abstract]

2022 May 27;40(5):508-522. PMID: 35403694
Mol Med Rep

ISX promotes tumor migration and invasion in lung cancer by upregulating COL1A1 in vitro. [Abstract]

2026 Feb;33(2):77. PMID: 41480691
Exp Cell Res

HPRT promotes proliferation and metastasis in head and neck squamous cell carcinoma through direct interaction with STAT3. [Abstract]

2021 Feb 1;399(1):112424. PMID: 33340493
Viruses

Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19). [Abstract]

2020 Jun 10;12(6):628. PMID: 32532085
Exp Cell Res

Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia. [Abstract]

2020 Aug 1;393(1):112054. PMID: 32376287
Saudi Pharm J

Augmented antitumor effects of erlotinib and cabozantinib on A549 non-small cell lung cancer: In vitro and in vivo studies. [Abstract]

2023 Oct;31(10):101756. PMID: 37705877
J Cancer

TRPV3 regulates Breast Cancer Cell Proliferation and Apoptosis by EGFR/AKT pathway. [Abstract]

2024 Mar 25;15(10):2891-2899. PMID: 38706904
Mol Carcinog

Epidermal growth factor receptor signaling in precancerous keratinocytes promotes neighboring head and neck cancer squamous cell carcinoma cancer stem cell-like properties and phosphoinositide 3-kinase inhibitor insensitivity. [Abstract]

2022 Jul;61(7):664-676. PMID: 35417043
Cancer Med

Proton pump inhibitors stabilize the expression of PD-L1 on cell membrane depending on the phosphorylation of GSK3β. [Abstract]

2024 May;13(10):e7083. PMID: 38752436

Erlotinib purchased from MedChemExpress. Usage Cited in: Cancer Med. 2024 May;13(10):e7083. [Abstract]

FACS analysis was used to perform the MFI of cell membrane of PD‐L1 in H441 cells with control or multiply small molecular inhibitors (Seen in the Table 1, 24 h) (n = 3). AV412 (HY‐10346; 20, 50 nM), ERK1/2 inhibitor 1 (HY‐112287; 20, 50 nM), AR‐A014418 (HY‐10512; 100, 200 nM), Erlotinib (HY‐50896; 50, 100 nM).
Cancer Med

MYST1/KAT8 contributes to tumor progression by activating EGFR signaling in glioblastoma cells. [Abstract]

2019 Dec;8(18):7793-7808. PMID: 31691527

Erlotinib purchased from MedChemExpress. Usage Cited in: Cancer Med. 2019 Dec;8(18):7793-7808. [Abstract]

Western blots of proteins expression in EGFR signaling pathways in LN229 and U87 cells with MYST1/GFP overexpression after erlotinib (200 ng/mL)/DMSO treatment.
Breast Cancer Res Treat

IGF1R activates FOXP3-β-catenin signaling to promote breast cancer development. [Abstract]

2025 Jun;211(2):467-478. PMID: 40055251
PLoS One

2026 Apr 24;21(4):e0347843.
PLoS One

A novel small molecule screening assay using normal human chondrocytes toward osteoarthritis drug discovery. [Abstract]

2024 Nov 1;19(11):e0308647. PMID: 39485774
Cancer Manag Res

Deguelin Restores Paclitaxel Sensitivity in Paclitaxel-Resistant Ovarian Cancer Cells via Inhibition of the EGFR Signaling Pathway. [Abstract]

2024 May 28:16:507-525. PMID: 38827785
PLoS One

Validated UPLC-MS/MS method for the quantification of dasatinib in plasma: Application to pharmacokinetic interaction studies with nutraceuticals in Wistar rats. [Abstract]

2018 Jun 14;13(6):e0199208. PMID: 29902246
PeerJ

Daidzein alleviates osteoporosis by promoting osteogenesis and angiogenesis coupling. [Abstract]

2023 Oct 16:11:e16121. PMID: 37868048
Thorac Cancer

Potential monoamine oxidase A inhibitor suppressing paclitaxel-resistant non-small cell lung cancer metastasis and growth. [Abstract]

2020 Oct;11(10):2858-2866. PMID: 32875729
Biomed Res Int

A Pharmacokinetic Interaction Study of Sorafenib and Iced Teas in Rats Using UPLC-MS/MS: An Illustration of Beverage-Drug Interaction. [Abstract]

2019 Nov 28;2019:2410845. PMID: 31871933
Biochem Biophys Res Commun

2026 Feb 12:800:153165. PMID: 41548485
Biochem Biophys Res Commun

Investigating NanoLuc-EGFR engineered cell lines for real-time monitoring of EGFR protein dynamics in live cells. [Abstract]

2024 Sep 19:733:150711. PMID: 39312880
Biochem Biophys Res Commun

A Beclin 1-targeting stapled peptide synergizes with erlotinib to potently inhibit proliferation of non-small-cell lung cancer cells. [Abstract]

2022 Dec 25;636(Pt 1):125-131. PMID: 36332474
J Med Food

Naturally Occurring Hair Growth Peptide: Water-Soluble Chicken Egg Yolk Peptides Stimulate Hair Growth Through Induction of Vascular Endothelial Growth Factor Production. [Abstract]

2018 Jul;21(7):701-708. PMID: 29583066
Biomed Chromatogr

A novel, sensitive, and fast ultra-high-performance liquid chromatography tandem mass spectrometry method for TNG908 determination in dog plasma and pharmacokinetic study. [Abstract]

2024 Nov 7:e6039. PMID: 39510096
Biomed Chromatogr

Simultaneous and rapid determination of gefitinib, erlotinib and afatinib plasma levels using liquid chromatography/tandem mass spectrometry in patients with non-small-cell lung cancer. [Abstract]

2016 Jul;30(7):1150-4. PMID: 26525154
Am J Transl Res

Ellagic acid inhibits cell proliferation, migration, and invasion in melanoma via EGFR pathway. [Abstract]

2020 May 15;12(5):2295-2304. PMID: 32509220
Biol Methods Protoc

Optimizing drug sensitivity assays in patient-derived tumor organoids: a comparison of IC50 estimation methods and experimental parameters. [Abstract]

2025 Feb 13;10(1):bpaf012. PMID: 40060949
bioRxiv

2026 Apr 15.
Res Sq

2026 Apr 28.
bioRxiv

2026 Mar 25.
bioRxiv

2026 Jan 27.
bioRxiv

2026 Jan 17.
bioRxiv

2026 Jan 9.
bioRxiv

2025 Sep 21.
Res Sq

An EGFR Co-Amplified and De Novo Long Noncoding RNA HELDR Promotes Glioblastoma Malignancy through KAT7-Driven Gene Programs. [Abstract]

2025 Jun 24:rs.3.rs-6456987. PMID: 40678238
Complutense University of Madrid

2025.
Patent

US20240344020A1
bioRxiv

BRAFV600 and ErbB inhibitors directly activate GCN2 in an off-target manner to limit cancer cell proliferation. [Abstract]

2024 Dec 20:2024.12.19.629301. PMID: 39763857
Patent

US20240344020A1.
Research Square Preprint

2024 Nov 26.
bioRxiv

LKB1 suppresses growth and promotes the internalization of EGFR through the PIKFYVE lipid kinase. [Abstract]

2023 Oct 20:2023.10.19.563158. PMID: 37904985
Research Square Preprint

2022 Jun.
Cell Insight

Phosphorylated STYK1 restrains the inhibitory role of EGFR in autophagy initiation and EGFR-TKIs sensitivity. [Abstract]

2022 Jun 16;1(4):100045. PMID: 37192859
bioRxiv

October 28, 2021.
SSRN

31 Aug 2021.
Research Square Preprint

2021 May.
bioRxiv

2019 Sep.
Oncotarget

Molecular-genetic profiling and high-throughput in vitro drug screening in NUT midline carcinoma-an aggressive and fatal disease. [Abstract]

2017 Dec 2;8(68):112313-112329. PMID: 29348827

Solvent & Solubility

In Vitro:

DMSO : 33.33 mg/mL (84.71 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.5417 mL

12.7084 mL

25.4168 mL

5 mM

0.5083 mL

2.5417 mL

5.0834 mL

10 mM

0.2542 mL

1.2708 mL

2.5417 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1.25 mg/mL (3.18 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 1.25 mg/mL (3.18 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 10 mg/mL (25.42 mM); Suspended solution; Need ultrasonic

Protocol 2

Add each solvent one by one: 0.5% CMC-Na/saline water

Solubility: 10 mg/mL (25.42 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (293 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Li S, et al. Ephrin A1 functions as a ligand of EGFR to promote EMT and metastasis in gastric cancer. The EMBO journal. 2025 Mar;44(5):1464-1487. [Content Brief]

[2]. Ferrarone JR, et al. Genome-wide CRISPR screens in spheroid culture reveal that the tumor suppressor LKB1 inhibits growth via the PIKFYVE lipid kinase. Proceedings of the National Academy of Sciences of the United States of America. 2024 May 21;121(21):e2403685121. [Content Brief]

[3]. Rysz MA et al. Erlotinib-A substrate and inhibitor of OATP2B1: pharmacokinetics and CYP3A-mediated metabolism in rSlco2b1-/- and SLCO2B1+/+ rats. Drug Metab Dispos. 2025 May;53(5):100069. [Content Brief]

[4]. Sun X, et al. Matrix metalloproteinase-10 promotes kidney fibrosis by transactivating β-catenin signaling. Cell death discovery. 2025 May 17;11(1):241. [Content Brief]

[5]. Ito F, et al. GRHL2-HER3 and E-cadherin mediate EGFR-bypass drug resistance in lung cancer cells. Frontiers in cell and developmental biology. 2024;12:1511190. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.5417 mL	12.7084 mL	25.4168 mL	63.5421 mL
	5 mM	0.5083 mL	2.5417 mL	5.0834 mL	12.7084 mL
	10 mM	0.2542 mL	1.2708 mL	2.5417 mL	6.3542 mL
	15 mM	0.1694 mL	0.8472 mL	1.6945 mL	4.2361 mL
	20 mM	0.1271 mL	0.6354 mL	1.2708 mL	3.1771 mL
	25 mM	0.1017 mL	0.5083 mL	1.0167 mL	2.5417 mL
	30 mM	0.0847 mL	0.4236 mL	0.8472 mL	2.1181 mL
	40 mM	0.0635 mL	0.3177 mL	0.6354 mL	1.5886 mL
	50 mM	0.0508 mL	0.2542 mL	0.5083 mL	1.2708 mL
	60 mM	0.0424 mL	0.2118 mL	0.4236 mL	1.0590 mL
	80 mM	0.0318 mL	0.1589 mL	0.3177 mL	0.7943 mL

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Erlotinib

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Kinase Inhibitor Library

Protein Tyrosine Kinase Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

CNS-Penetrant Compound Library

Autophagy Compound Library

Drug Repurposing Compound Library

Differentiation Inducing Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Hepatitis C Virus Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Targeted Therapy Drug Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Anti-Liver Cancer Compound Library

Rare Diseases Drug Library

Anti-Colorectal Cancer Compound Library

Protein-protein Interaction Inhibitor Library

Chemotherapy Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Off-patent Drug Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Mitochondrial Toxicity Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cytokine Inhibitors Library

Cell Death Library

Anti-Ovarian Cancer Compound Library

Radiosensitizer Library

Bioactive Compound Library Max

Kinase Inhibitor Library Mini

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Anti-Cancer Approved Drug Library

Mass Spectrometry Human Metabolite Library

Posttranslational Modification Library

Nephrotoxicity Compound Library

FDA Kinase Inhibitor Library

RNA Binding Bioactive Compound Library

Alkyne Compound Library

Publications Citing Use of MedChemExpress (MCE) Erlotinib

All EGFR Isoforms

All ERK Isoforms

All GSK-3 Isoforms

Biological Activity

Chemical Information

Publications (138)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Erlotinib Related Classifications

Cat. No.: HY-50896